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SUMMARY 
 
Over the past decade, the scientific research spent many efforts to develop 
therapeutic and diagnostic systems able to contact selectively the target cells and to 
minimize their diffusion in healthy organs. For this purpose the most diffuse approach 
was targeting the molecular markers overexpressed on the tissues of interest. In this 
contest, the integrin family of cell adhesion receptors was one of the most studied 
markers. (Tucker G.C., 2006).  
In particular, among all integrins, v 3 receptor was particularly studied in the last 
decade. Physiologically, it mediates many different biological processes such as 
intracellular signalling, cell migration, proliferation, and survival through interactions 
with ECM proteins such as vitronectin, fibronectin and osteopontin. The receptor 
mediates cell adhesion to extracellular matrix by recognizing the conserved Arg-Gly-
Asp sequence of several plasma and matrix proteins. It is strongly overexpressed in 
activated EC, melanoma, glioblastoma and prostate cancers and in granulation 
tissue, whereas is not detectable in quiescent blood vessels or in the dermis and 
epithelium of normal skin. Therefore it can be considered a tumour and activated 
endothelium marker.  
In the last decade several αvβ3 ligands able to modulate the receptor activity were 
developed as drugs for therapy, as tracers for diagnosis and as ligands for targeted 
drug delivery systems.   
Among these molecules, the pentapeptide c(RGDf[NMe]V), also known as  
Cilengitide, is the most active , αvβ3/αvβ5 antagonist reported in literature and is in 
phase III clinical trials as antiangiogenic drug for glioblastoma therapy 
(Dechantsreiter M.A., et al., 1999; Reardon D.A., 2008; Tabatabai G., et al., 2010). 
However, even if all v 3 ligands reported in the literature have  a good  affinity for 
the receptor, they present a low selectivity and bind, even if with lower affinity, also 
other integrin receptors structurally homologues of v 3 such as v 5 integrin (Smith 
J.W., et al., 2003; Eskens F.A., et al., 2003). In contrast with v 3 that has a 
relatively limited cellular distribution v 5 is widely expressed by many malignant 
tumor cells.  
Therefore, to target v 3-mediated processes for diagnostic or therapeutic purposes, 
the development of new compounds that can discriminate between v 3  and v 5   
is required to minimize the side-effects and increase the therapeutic effectiveness. 
In 2006 our research group designed and synthesized a novel and selective peptide 
antagonist, referred to as RGDechiHCit, to visualize αvβ3 receptor on tumour cell 
(Del Gatto A., et al., 2006). It is a chimeric peptide containing a cyclic RGD motif and 
two echistatin C-terminal moieties covalently linked by spacer sequence. Cell 
adhesion assays showed that RGDechiHCit selectively binds, αvβ3 integrin and does 
not cross-react with, αvβ5 and, αIIbβ3 integrins (Del Gatto A., et al., 2006). 
Furthermore, PET and SPECT imaging studies confirmed that the peptide selectively  
localizes on αvβ3 expressing tumor cells in xenograft animal model (Zannetti A., et 
al., 2009). In this experimental setting, the chimeric RGDechiHCit was not able to 
detect a signal originating from the newly formed intratumoral blood vessels. This 
may be due to incomplete neovascularization and, hence, low levels of αvβ3 
expression or to the murine origin of the integrin on newly formed blood vessels 
because the rational design of the chimeric RGD peptide was based on the crystal 
structure of the extracellular region of human αvβ3. Therefore the main purpose of 
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the present PhD thesis was to evaluate in vitro and in vivo effects of RGDechiHCit on 
neovascularization. 
In particular, we first assessed the in vitro peptide properties on bovine aortic ECs, 
VSMC and then in vivo, in Wistar Kyoto (WKY) rats and c57BL/6 mice, the ability of 
this cyclic peptide to inhibit angiogenesis in comparison with Cilengitide. 
A major evidence that is brought up by our results is the peculiar selectivity of 
RGDechiHCit towards EC, as compared to c(RGDf[NMe]V). Indeed, RGDechiHCit 
fails to inhibit VSMC proliferation in vitro, opposite to c(RGDf[NMe]V). This feature 
could be due to the selectivity of such a novel compound towards , αvβ3, VSMCs 
indeed express αvβ3 only during embryogenesis (Eliceri B.P., et al., 1998; Illario M., 
et al., 2005), but express other integrins which may be blocked by c(RGDf[NMe]V). 
On the contrary, αvβ3 is expressed on ECs, thus conferring RGDechiHCit selectivity 
toward this cell type. It is only an indirect evidence, that needs further investigation in 
following experiments. Comparable results between the two antagonists were 
obtained on wound healing and Matrigel plugs invasion. Our data suggest that 
inhibition of the endothelial integrin system is sufficient to inhibit angiogenesis.  
In conclusion the potential antiangionenic activity of the peptide opens new fields of 
application for the treatment of pathophysiological conditions associated to 
angiogenesis such as cancer, proliferative retinopathy and inflammatory disease. 
In the nanotechnology field,  gold nanoparticles (AuNPs) are playing a pivotal role in 
providing new types of targeted delivery systems to permit the selective entry of one 
or multiple drugs in the primary tumor, as well as at the site of metastasis and its 
microenvironment. AuNPs can be indeed used to deliver a cargo, such as an 
anticancer drugs, or a radionuclide to tumor sites as well they can be also employed 
in tumor phothermal therapy for their plasmon resonance properties (Melancon M., et 
al., 2009). In both cases the targeted drug approach is achieved by the exploitation of 
molecular markers over-expressed in cancerous tissues such as αvβ3 integrin.  
Unfortunately, nanogold  tend to aggregate in solution and so it is difficult to preserve 
them for long time. To solve this issue they can be functionalized with various organic 
ligands to create organic-inorganic hybrids with advanced functionality. It was 
recently reported the use of peptide sequences based on the GC repeats as 
stabilizing agents for the preparation of monolayer gold nanoparticles (Krpetić Z., 
2009).  
On the basis of this data, we designed and synthesized a new chimeric peptide 
(thereafter named RGD(GC)2, displaying motifs for both targeting and capping 
functions. A RGD-containing peptide, derived from the Cilengitide, was chosen as a 
targeting ligand for, αvβ3 integrin receptor and a GC including peptide was selected 
in order to stabilize  the gold nanoparticles. AuNPs functionalised with this peptide 
were prepared and characterized by Uv-Vis, ATR-IR, XRD, NMR techniques and 
TEM microscopy.  Finally we tested the ability of the obtained nanosystems, named 
RGD(GC)2AuNPs, to permeate the target cells membrane (U-87 MG, glioblastoma 
cells). In all these studies we used as negative control peptide named (GC)2 
corresponding to the capping motif obtaining the gold nanoparticles named 
(GC)2AuNPs. 
Our results encourage us to retain that  this system could be a good starting point to 
develop selective gold nanodevices useful in the field of biotechnologies for 
therapeutic and diagnostic applications. 
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RIASSUNTO 
 
Negli ultimi anni numerosi studi hanno dimostrato che molte delle patologie 
attualmente più diffuse sono caratterizzate dall’ iperespressione di alcune molecole 
considerate come marcatori molecolari (Wehrle-Haller B., et al., 2003).  
Per questo motivo, al fine di ottenere una maggiore specificità sia nella cura che 
nella diagnosi delle malattie, la ricerca, in particolare nel campo delle biotecnologie, 
ha avuto come principale obiettivo dei propri studi lo sviluppo di specifici sistemi 
bersaglio basati sul riconoscimento dei marcatori molecolari overespressi dalle 
cellule malate (Gordon C.T., 2006).  
In quest’ambito, ha destato un grande interesse nella comunità scientifica una 
famiglia di recettori di adesione cellulare presente sulla superficie di vari tipi di cellule 
e coinvolta in importanti processi biologici: le integrine.  
Le integrine sono glicoproteine eterodimeriche appartenenti alla famiglia dei recettori 
di adesione cellulare la cui principale funzione consiste nell’integrare e mettere in 
comunicazione l’esterno della cellula (ECM) con il suo l’interno (citoscheletro). Esse 
sono costituite da una subunità α ed una subunità β legate in modo non covalente 
che attraversano la membrana cellulare. Nei mammiferi sono attualmente noti 
almeno 24 eterodimeri diversi di integrina composti da 18 tipi di subunità α ed 10 tipi 
di subunità β. Una singola catena β può interagire con numerose catene α formando 
vari tipi di recettori che legano specifici ligandi dando il via a molteplici eventi cellulari 
(Hynes R.O. et al.,1996; Takada Y.et al., 2003). Difatti, in seguito all’interazione con 
determinate molecole dell’ ECM, le integrine formano dei cluster molecolari ed 
attivano uno o più pathway di segnali intracellulari quali chinasi (serina/treonina 
chinasi e  MAP chinasi), recettori per fattori di crescita, canali ionici e determinano il 
controllo dell’organizzazione del citoscheletro, necessari per la sopravvivenza, la 
proliferazione, il differenziamento e la migrazione cellulare (Eliceri B.P., et al.,1999).  
In particolare, notevole attenzione è stata rivolta all’ integrina αvβ3, overespressa 
sulla superficie delle cellule vascolari di molti tessuti tumorali e coinvolta in importanti 
processi biologici tra cui l’angiogenesi ossia, la formazione di nuovi vasi sanguigni a 
partire da capillari preesistenti (Liu Z., et al., 2008). Tale processo si verifica 
principalmente durante lo sviluppo embrionale mentre negli individui adulti avviene in 
caso di rimarginazione di ferite, ciclo mestruale e gravidanza ed è finemente regolato 
dall’equilibrio tra fattori pro-angiogenici ed anti-angiogenici. In presenza di particolari 
stimoli quali ipossia, stress cellulare, insorgenza di un tumore, tale equilibrio si altera 
ed i fattori pro-angiogenici, tra cui anche l’integrina  αvβ3, prevalgono in maniera 
incontrollata dando luogo alla così detta “angiogenesi patologica”, alla base della 
sopravvivenza e della metastasi della massa cancerosa. 
 Dato il rilevante ruolo biologico esercitato dall’integrina αvβ3, negli ultimi anni sono 
state sintetizzate numerose molecole capaci di modularne l’attività.  
Fra i più noti ligandi di natura peptidica si considera il potente peptide ciclico 
Cilengitide, attualmente in Fase III di valutazione clinica per la terapia 
antiangiogenica del glioblastoma (Dechantsreiter M.A., et al., 1999; Reardon D.A., 
2008; Tabatabai G., et al., 2010). Tuttavia, tale molecola presenta un limite: non è 
selettiva per l’integrina αvβ3, difatti lega, anche se con minore affinità, anche altre 
integrine strutturalmente omologhe ad essa quali αvβ5 ed α1β5. 
Tra le varie molecole sviluppate, di recente, è stato realizzato un nuovo ligando 
selettivo per l’integrina αvβ3 denominato RGDechiHCit (Del Gatto A., et al., 2006). 
Tale molecola è stata ottenuta legando covalentemente, mediante un opportuno 
linker, una porzione ciclica riconducibile alla sequenza del peptide Cilengitide ed una 
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porzione lineare derivata dai residui localizzati all'estremità C-terminale 
dell'Echistatina (un antagonista naturale della suddetta integrina). Saggi di adesione 
cellulare hanno dimostrato che tale peptide è capace di inibire l'adesione di cellule 
sovraesprimenti αvβ3 in modo altamente selettivo e con un’affinità di legame 
paragonabile alla Cilengitide. Inoltre, saggi in vivo hanno dimostrato che il peptide, 
opportunamente funzionalizzato è capace di visualizzare attraverso diverse tecniche 
di imaging molecolare quali SPETCT e PET (Zannetti A., et al., 2009). Nell’ambito di 
tali studi, il peptide RGDechiHCit non si è rivelato utile nella visualizzazione dei 
neovasi sanguigni  intratumorali. Si è ipotizzato che ciò sia dovuto alla incompleta 
neovascolarizazione e, di conseguenza, ai bassi livelli di espressione  dell’integrina 
αvβ3, oppure  al fatto che i neovasi siano di natura murina e il peptide sia stato, 
invece, progettato sulla base dell’ integrina αvβ3 umana. Per tale ragione, uno dei 
principali obiettivi della presente tesi di dottorato è stato lo studio dell’attività 
antiangiogenica, sia in vivo che in vitro, del peptide RGDechiHCit sulle cellule 
vascolari.  
A tal scopo, in collaborazione con i ricercatori del Dipartimento di Medicina Clinica, 
Scienze Cardiovascolari ed Immunologiche dell’ Università degli studi di Napoli 
Federico II sono stati effettuati diversi esperimenti in vitro (saggi di adesione e 
proliferazione cellulare e studi dell’angiogenesi in vitro utilizzando preparazioni di 
Matrigel) su cellule vascolari endoteliali bovine (BAEC) e su cellule muscolari 
vascolari liscie (VSMC).  
I saggi effettuati hanno dimostrato che il peptide RGDechiHCit è in grado di inibire l’ 
l’angiogenesi. L’attività antagonista del peptide RGDechiHCit è stata confermata 
anche in vivo valutando l’effetto sulla cicatrizzazione delle ferite in modelli murini 
(Wound healing). In presenza del peptide in esame, infatti, il tempo di rimarginazione 
delle ferite praticate risulta maggiore rispetto alle ferite non trattate (Santulli G., et al., 
SUBMITTED) .  
Sulla base dei buoni risultati ottenuti, possiamo quindi considerare RGDechiHCit un 
buon punto di partenza per lo sviluppo di molecole in grado di legare ed inibire 
selettivamente l’attività. Studi per migliorare la stabilità in siero del suddetto peptide 
ed identificarne la minima sequenza dotata di pari affinità e selettività per l’integrina 
αvβ3 sono attualmente in corso.  
Di recente, la ricerca biotecnologica ha investito molte energie per sfruttare la 
capacità dei peptidi di riconoscere specifici recettori al fine di ottenere dei sistemi 
terapeutici selettivamente diretti sulle cellule overesprimenti i marcatori  molecolari 
(Lim Y., et al., 2008) quali l’integrina αvβ3. In questo modo, una radiomolecola o un 
agente terapeutico è guidato dal peptide fino alla cellula target con una efficacia 
molto maggiore rispetto alle cellule normali. Negli ultimi anni, di conseguenza, si è 
verificato un notevole incremento dello sviluppo dei cosiddetti nano vettori (micelle, 
liposomi) ed aggregati di nano particelle d’oro (nanogold) che trovano utilità sia nel 
drug delivery che nel campo delle tecniche di imaging molecolare.  
Pertanto, parallelamente, l’attività di ricerca è stata rivolta anche allo sviluppo di una 
nuova sequenza peptidica per la funzionalizzazione di nanoparticelle di oro  allo 
scopo di sviluppare un sistema selettivo per il targeting dell’integrina αvβ3 con 
applicazioni sia in campo diagnostico che terapeutico.  
Recentemente è stato riportato in letteratura che peptidi contenenti la sequenza GC 
sono capaci di stabilizzare le nanoparticelle di oro e di sfavorirne l’aggregazione in 
soluzione (Krpetić Z., 2009). L’aggregato ottenuto, può essere utilizzato sia come 
veicolo per il trasporto dei farmaci e  di agenti traccianti che per la terapia fototermica 
grazie alle sue proprietà ottiche (Melancon M., et al., 2009). 
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Partendo da tali informazioni, è stato progettata una sequenza peptidica di tipo 
chimerico, RGD-(GC)2, formata da una sequenza contente il motivo GC ripetuto due 
volte ed un peptide ciclico analogo della Cilengitide. II peptide, è stato sintetizzato in 
fase solida utilizzando la chimica Fmoc ed amminoacidi opportunamente protetti.  
Le nano particelle d’oro sono state preparate in un’unica reazione mediante riduzione 
dell’acido tetracloroaurico con boroidrato in presenza del peptide stabilizzante 
c(RGDfE)AGCGGCG-NH2 in collaborazione con il Dipartimento di Chimica 
Inorganica, Metallorganica ed Analitica “L. Malatesta”  ed il Dipartimento di Biologia 
dell’Università di Milano. Istantaneamente si è formata una limpida soluzione rossa 
indice della formazione di nanoparticelle d’oro del diametro di circa 8.5 nm. Le 
particelle sono state purificate tramite dialisi. La funzionalizzazione e la dimensione 
delle nanoparticelle sono state verificate mediante UV-Vis, TEM, FTIR ed NMR. 
Inoltre, sono stati effettuati studi in vitro, su cellule di glioblastoma, per verificare la 
capacità delle nano particelle ottenute di penetrare nelle cellule bersaglio. Tutti gli 
studi effettuati, sono stati ripetuti usando il peptide aspecifico (GC)2, da noi progettato 
e sintetizzato per disporre di un controllo negativo. Tale peptide, difatti, corrisponde 
alla molecola RGD-(GC)2  priva del motivo RGD. I risultati ottenuti hanno rivelato 
un’alta efficienza di internalizzazione cellulare dopo soli 5 minuti di trattamento.  
Ulteriori studi mirati alla comprensione del meccanismo di incorporazione delle nano 
particelle funzionalizzate sono tutt’ora in corso. Le numerose informazioni strutturali 
ricavate dallo studio delle nano particelle d’oro funzionalizzate, ottenute durante il 
presente lavoro di dottorato, aprono la strada alla progettazione e alla sintesi di nuovi 
e più efficaci sistemi diagnostici e terapeutici volti ad minimizzare gli effetti collaterali 
di agenti terapeutici e diagnostici.  
Attualmente sono in allestimento esperimenti volti a chiarire il meccanismo con cui le 
nano particelle sono incorporate nelle cellule bersaglio e stabilire esattamente la 
quantità di molecole presenti sulla superficie di ciascun aggregato. In tal modo sarà 
possibile controllare il grado di funzionalizzazione del nanosistema ottenuto ed 
aumentarne l’efficienza. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
1 INTRODUCTION 
 
It is known that one of the primary goal of a successful pathology treatment and 
diagnosis is to target selectively the tissues of interest while minimizing the drug 
distribution in normal organs.  
In cancer therapy the standard agents enter in normal tissues with indiscriminate 
cytotoxicity and do not preferentially accumulate at tumour sites. In same cases, the 
dose reaching the target organs may be also as little as 5% to 10% of the doses 
accumulating in normal tissues (de Bono J. S., et al., 2010). In this way, the 
pharmaceutical effect is decreased and the toxic effect to normal cells is increased. 
In diagnostic field, the problems in the delivery of contrast agents are essentially the 
same as for therapeutic pharmaceuticals. Many tracers are indeed aspecifically 
captured from the normal tissues and they do not arrive in a sufficient quantity to the 
target organs failing the diagnosis of the pathology (Sugahara K.N., et al, 2009). 
To solve these issues, in last decade, the scientific community spent many efforts to 
develop selective therapeutic and diagnostic systems. 
Several approaches have been focused on improvement of the ability of anticancer 
drugs and contrast agents to avoid normal organs. One of the most effective 
strategies is the development of compounds able to target selectively markers 
overexpressed in tumour tissues. 
Another strategy is to encapsulate drugs in particles (such as liposomes, micelles 
and nanovectors) that, opportunely functionalised with moiety able to recognize 
tumour markers, are able to selectively delivery the drug into cancer cells (targed 
drug delivery approach).  
For both strategies, the integrins cell adhesion receptors represent appealing tumour 
markers to obtain selective compounds for therapeutic and diagnostic applications.  
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1.1 INTEGRINS 
 
1.1.1 Structural informations 
 
Integrins are a family of transmembrane receptors present on multiple types of cell 
surface that mediate cell–cell and cell–ECM (extracellular matrix) interactions.  
On a structural point of view, they consist of α and β heterodimers which associate 
non-covalently in defined combinations. At least 24 distinct integrin heterodimers are 
formed by the combination of 18 α-subunits and 10 β-subunits both characterized by 
a large N-terminal extracellular domain, a transmembrane domain, and a short C-
terminal intracellular tail. (Cox D., et al., 2010; Hynes R.O. et al.,1996; Takada Y., et 
al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outside the cell plasma membrane, α and β subunits form a binding pocket for ECM 
ligands (Takada Y., et al., 2007) that contain a specific structural element named I 
domain (also termed A-domain). In some integrins (e.g.  α1β1 and α2β1), this 
peculiar site  is inserted on the α chain toward the N-terminus. The receptors carrying 
this domain either bind to collagens, or act as cell-cell adhesion molecules (integrins 
of the β2 family) (Xiao T., et al., 2004). Those integrins that not presenting this 
inserted site in α chain, also have an I domain in their β subunit like  αvβ3 and α5β1. 
In both cases, the I domain contains the MIDAS (metal ion-dependent adhesion site), 
a ligand binding site permanently occupied by divalent cations and containing either 
a Ca++ or Mg++ ion. In addition there are two adjacent metal ion-binding sites that 
bind Ca++ named LIMBS (ligand-induced metal ion-binding site) and ADMIDAS 
(adjacent to metal ion-dependent adhesion site) respectively (Takagi J., et al., 2002). 
These regions interact with negatively charged residues in ligands. Indeed, the ligand 
aspartic acid-based sequences (e.g. RGD, LDV, KGD, RTD and KQAGD) bind to the 
majority of integrin ligands (Arnaout M.A., et al., 2002) (Figure 2).  
In particular, the most diffused negative charged amino acid motif in the integrin-
interaction site of ECM adhesive proteins (vitronectin, osteopontin, etc), is the amino 
acid sequence Arginine-Glycine-Aspartic acid ("RGD" in the one-letter amino acid 
code). So, different integrins bind ligands encompassing this amino acidic sequence 
(Humphries M.J., et al., 2003, Xiong J.P., et al., 2003). 
 
 
 
Fig. 1  Integrin family (Cox
 
D., et al., 2010). 
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Nevertheless, even if different integrins recognise different proteins containing RGD 
sequences, the contest of the RGD sequence (flanking residues, three dimensional 
presentation and individual features of the integrin binding pockets) determines the 
specificity and the efficacy of interaction (Zaccaro L., et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 The ligand binding site of αvβ3. Ligand is in yellow. The three  metal ions present in the liganded form 
(LIMBS, MIDAS, and ADMIDAS) are shown in gray, cyan, and magenta, respectively (Xiong J.P., et al., 
2003). 
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1.1.2 Activation and biological role 
 
Integrin extracellular domain binds directly components of the ECM and provides the 
traction necessary for cell motility. For this reason, integrins are usually classified as 
“adhesion molecules” but they are also important “signalling molecules”. Indeed, the 
integrin interactions with their ligands induce conformational changes in the 
extracellular domains leading to an increase in the affinity for ligands themselves as 
well as associations of integrins into clusters. This event, named “outside-in 
signaling” leads to the activation of different intracellular pathways like tyrosine and 
serine/threonine kinases activation, MAP kinases and other effectors proteins 
supporting the migration, proliferation and cellular differentiation (Legate K.R., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moreover, integrins modulate their activity also through another mechanism named 
“inside-out signalling”. In their resting state, integrins normally bind their ligands with 
low affinity; upon intracellular stimulation, a cellular signal induces a conformational 
change in the integrin cytoplasmic domain that propagates to the extracellular 
domain leading to a transformation of receptor from a low to a high affinity ligand 
binding state (Harburger D.S., et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Integrin inside-out signaling (Harburger D. S., et al., 2009). 
 
Fig. 3  Integrin outside-in signaling (Legate K. R., 2009). 
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1.1.3 Integrins and disease 
 
Due to their crucial biological role, integrins are involved in a variety of different 
pathologies. One of the human disease caused by integrin defects is the Leucocyte 
Adhesion Deficiency type I (LAD-1), an autosomal recessive disorder of the immune 
system characterized by recurrent infections that are frequently life-threatening. It is 
caused by impaired extravasion of poli morpho nucleate cells and monocytes due to 
absence or mutation of β2-integrins (Anderson D.C., et al., 1987).  
Another important pathology is the Glanzmann thrombasthenia. This is a disease 
caused by the failure of the platelet αIIβ3-integrin to make contacts with fibrinogen 
and fibrin, resulting in platelet dysfunction and prolonged bleeding time (Nair S., et 
al., 2002). 
Moreover, integrins are implicated in epidermial disorders such as Epidermolysis 
bullosa, an autosomal recessive epidermal blister condition of the skin. It is due to 
the failure of the α6- or β4-integrin subunit to be expressed in functional heterodimer. 
This, induces disruption of the mechanical link between the basement membrane 
and the basal keratinocyte layer (Jonkmar M.F., 2002). 
The integrins are also involved in many processes fundamental for the initiation, 
progression and metastasis of solid tumours and some of them are overexpressed 
on the cancer cells surface. Indeed, studies correlating integrin expression levels in 
human tumours with pathological outcomes, such as patient survival and metastasis, 
have identified several integrins that might have an important role in cancer 
progression. To date it is known that tumour cell expression of αvβ3, αvβ5, α5β1, 
α6β4, α4β1 and αvβ6 integrins is correlated with disease progression in different 
tumours (TABLE 1). The relevant environment of integrins in several pathologies has 
made them an interesting target for cancer therapy and diagnosis (Desgrosellier J.S., 
et al., 2010). 
 
 
 
 
 
 
 
 
TAB.1 Integrins involvement in  cancer progression (Desgrosellier J.S., et al., 2010). 
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1.2 αvβ3 INTEGRIN 
 
1.2.1 Structural informations 
 
Integrin αvβ3 consists of a 125 kDa αv subunit and a 105 kDa β3 subunit. In 2001, 
crystal structure of the extracellular segment of integrin αvβ3 has been solved by X-
Ray diffraction (Xiong J.P., et al 2001) (Figure 7). As was recently confirmed, the X-
Ray structure shows that the heterodimeric molecule can exist in either an “extended” 
or "flexed" conformation (Xiong J.P., et al., 2009) (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The available data indicate that the "flexed" or "bent" conformation represents the 
inactive form. The analysis of the crystallized conformer of αvβ3, resembles a large 
“head” on two “legs”. The head of the integrin, which is the minimal fragment that 
contains ligand-binding activity, comprises a β-propeller from the α subunit, an I 
domain from the β subunit (the β I domain) and an immunoglobulin “hybrid” domain 
below the β I domain. The α subunit leg of the integrin comprises three β sandwich 
domains, termed “thigh”, “calf1” and “calf2”. The β subunit leg contains a plexin-
semaphorin-integrin domain (PSI), which is disordered in the structure, four EGF-like 
(Epidermial growth factor) repeats and a cystatin-like fold. The bend in the integrin is 
between thigh and calf1 in αv and at the conjuction of the hybrid domain, the two 
EGF repeats and the PSI domain (in β3) (Xiong J. P., et al., 2004). 
In addition, in 2003, the crystal structure of αvβ3 in complex with an Arg-Gly-Asp 
ligand having sequence c(RGDf[NMeV]), the Cilengitide, a potent αvβ3 antagonist, 
actually in Phase III clinical trial for the glioblastoma treatment, was determined 
(Figure 9).  
 
 
Fig. 7  Integrin
 
αvβ3 crystal structure 
           (Xiong J.P., et al., 2001). 
 
 
 
 
Fig. 8  Integrin
 
αvβ3 ectodomain crystal 
structure (Xiong J.P., et al., 2009). 
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The crystal structure shown that the peptide is inserted in a space between the β 
propeller and the β I domain on the receptor head. The aspartic and arginine lateral 
chains are direct in opposite direction. The arginine residue is inserted in a groove on 
the bottom of the beta propeller of the alpha subunit and its guanidium group 
interacts with Asp218 and Asp150 lateral chains through salt bridges. The second Asp 
carboxyl oxygen forms hydrogen bonds with the backbone amides of Tyr122 and 
Asn215 and inteact with MIDAS metallic ions. Contrary to the arginine residue that is 
partially exposed to the solvent, aspartic acid is completely inserted into the binding 
site. The Gly residue, which completes the prototype RGD ligand sequence, lies at 
the interface between the α and β subunits. It makes several hydrophobic interactions 
with αv, the most critical of which appears to be the contact with the carbonyl oxygen 
of Arg216.  
The remaining two residues of the pentapeptide face are away from the αβ interface 
and are not interact with the receptor. Selectivity between different subunits is 
achieved by the RGD sequence conformation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 Crystal structure
 
of αvβ3 in complex with c(RGDf[NMeV]) (Xiong J.P., et al., 2004). 
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1.2.2 Phisiological and pathological role  
 
In the last decade, αvβ3 integrin attracted the attention of the scientific community as 
interesting target for development of new and selective systems for biotechnological 
applications. This receptor mediates many different biological processes such as 
intracellular signalling, cell migration, proliferation, and survival through interactions 
with the conserved Arg-Gly-Asp sequence of several plasma and matrix proteins 
(Harburger D. S., et al., 2009).   
αvβ3 integrin is expressed on a variety of cell types including smooth muscle cells 
(SMC), endothelial cells (EC), osteoclasts, leucocytes, platelet and mesangimal cells 
and it plays a crucial role in many pathological events.  
In osteoporosis, a chronic bone disease characterized by a decrease in bone mass 
resulting from accelerated osteoclast mediated bone resorption relative to formation 
(Nakamura I., et al., 2007), αvβ3 is expressed at high level in osteoclasts. In these 
cells, the receptor is implicated in the adhesion, activation, and migration on the bone 
surface as well as in osteoclast polarization. Therefore, inhibition of osteoclast-driven 
bone resorption by blocking αvβ3 integrin could be useful for the treatment of this 
disease.  
αvβ3 integrin is also implicated in the rheumatoid arthritis (RA), a chronic 
and systemic inflammatory disorder that may affect many tissues and organs, but 
mainly attacks synovial joints. Moreover, this integrin is overexpressed on 
activated macrophages and osteoclasts and these cell types are found in abundance 
at sites of bone destruction in rheumatoid arthritis patients. In these cases, activated 
macrophages are markedly increased in both subchondral bone and inflamed 
synovial tissues, and osteoclasts are markedly increased in subchondral bone at 
sites of bone erosion and resorption.  Consequently, osteoclast mediated bone 
resorption, macrophage dependent inflammation and inflammatory angiogenesis 
represent relevant pathogenic features of RA. Hence, these evidences support 
the view that inhibition of αvβ3 in the synovium of RA  patients may have therapeutic 
benefits (Perdih A., et al., 2010).  
Cell-matrix adhesion, migration and differentiation events that underlie restenosis 
after injury are mediated by αvβ3 integrin-ligand interactions. Different studies have 
shown that αvβ3 integrin mediates smooth muscle cell proliferation and accumulation 
in the arterial intima by the interaction with osteopontin that contributes to neointimal 
thickening in the setting of arterial ligation. Thereby, selective αvβ3 blockade could 
be an effective anti-restenosis strategy that limits neointimal growth and lumen 
stenosis following deep arterial injury in coronary angioplasty (i.e. PTCA) (Hodivala-
Dilke K., et al., 2008). 
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1.2.3 αvβ3 and angiogenesis 
 
Among the different diseases αvβ3 integrin is involved in the pathological 
angiogenesis was the most studied in the last years. Angiogenesis is the formation of 
new blood vessels starting from pre-existing capillaries. Physiologically this process 
verify during the embryo formation and, in adults, during menstruation, ovulation, 
pregnancy and wound healing.  
The mechanism of angiogenesis is very complex. In a simplified overview (Figure 5), 
the angiogenesis starts with the release of angiogenic factors which bind to their 
receptors on the membrane of ECs, allowing the transmission of the signal that leads 
to the transcription of several genes. Following angiogenic stimulus, the ECs express 
integrins, in particular αvβ3 which participates to the activation of vascular endothelial 
growth factor receptor-2 (VEGFR-2), providing a survival signal to the proliferating 
vascular cells during new vessel growth. Since a functional vascular network is 
formed, it is necessary that the new-formed vessel is remodelled to form a mature 
vessel. At this propose, platelets release the Platelet-derived growth factor (PDGF) 
as it stimulates the requirement of pericytes and smooth muscle cells which stabilise 
the morphology of the vessel and prevent the regression of endothelial cells (Harper 
J., 2006; Nyberg P., et al., 2008; Cristofanilli M. et al., 2002).  
 
 
 
 
 
 
 
 
Fig.5 A simple scheme of the angiogenesis processes (Cristofanilli M., et al., 2002). 
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Angiogenesis is regulated by the equilibrium between pro-angiogenic and anti-
angiogenic factors (Table 2). 
 
 
TAB. 2 Factors affecting EC proliferation and migration (Bou¨ıs D., 2006). 
 
The shift from this equilibrium (angiogenic switch), under specific stimuli such as 
hypoxia, is related to several human diseases (pathological angiogenesis) (Figure 6). 
The overexpression of antiangiogenic-factors, such as angiostatin or 
thrombospondin, is associated with chronic injury due to inhibition of capillaries 
growth and  prolonged bleeding consequent to inhibition of platelets aggregation (Mu 
W., et al., 2009). Instead, the prevalence of pro-angiogenic factor such as VEGF or 
αvβ3 integrin is associated with cancer, proliferating retinopathy and psoriasis 
(Folkman J., 2001).  
 To date, it was greatly reported that v 3 integrin receptor seems to be most closely 
associated with another integrin in angiogenesis process, v 5, playing an important 
role in tumour-induced angiogenesis. αvβ5 is widely expressed in many malignant 
tumour cells while αvβ3 has a relatively limited cellular distribution compared with that 
of αvβ5. In particular, v 3 integrin is normally expressed on mature endothelial cells 
but it is highly expressed on the activated ECs, in several tumour forms, including 
melanomas, ovarian and lung carcinomas, osteosarcomas, neuroblastomas, 
glioblastomas, and breast cancer. 
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Therefore, the development of new compounds that can discriminate between αvβ3 
and αvβ5 is required to target αvβ3-mediated processes for diagnostic or therapeutic 
applications. For this reason in last decade a variety of different compounds able to 
modulate αvβ3 biological activity was synthesised (Bachmann I.M., et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 A simple scheme of the tumor angiogenesis processes (www.wentek.com/jean/research.htm). 
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1.3  αvβ3 INTEGRIN: A THERAPEUTIC AND DIAGNOSTIC APPROACH 
 
1.3.1 αvβ3 integrin: synthetic ligands 
 
Most cancer drugs fail in clinical studies not because they are ineffective in killing 
cancer cells but because they cannot be administered in doses high enough to 
contrast the tumour without severely harming the patient. 
For this reason in recent years the design of high selective ligands represented a 
great challenge in cancer therapy. In particular, in biotechnological field, selective 
ligands could be used to deliver specifically therapeutic and diagnostic molecules into 
tumour cells.  
Many compounds as αvβ3 ligands were developed such as small organic molecules, 
peptidomimetics, cyclic and linear peptides. Specific monoclonal antibodies, as the 
human monoclonal antibody LM609 (named Vitaxin) now in phase II clinical trials for 
the antiangiogenic therapy of colorectal cancer, was also developed (Wilder R.L., et 
al., 2002).  
However, antibody-based compounds, despite the development of chimeric and 
engineered molecules, suffer of several limitations because of the long circulation 
half-life, the high background activity, the poor tumour penetration, and the no 
uniform intratumoral distribution. For these reasons, peptide-based probes, despite 
the lack of absolute integrin selectivity, are preferred because of small size, 
preparation by chemical and biological methods, functionalization and conjugation, 
low toxicity, low immunogenicity, a high affinity and specificity for receptors.  
Since different integrins recognise different proteins containing RGD sequences, the 
contest of the RGD sequence (flanking residues, three dimensional presentation and 
individual features of the integrin binding pockets) determines the specificity and the 
efficacy of interaction. For this reason, the actually available molecules in the 
literature were designed also thanks to information derived from Cilengitide-αvβ3 
integrin complex structure that stressed the conformational features of the RGD 
sequence and the main contacts essential for the receptor interaction. 
In 1999 Kesselr and co-workers designed and characterized the Cilengitide, the 
pentapeptide c(RGDf[NMe]V), (Dechantsreiter M.A., et al., 1999). This molecule  is 
one of the most potent αvβ3 antagonist and is now in phase III clinical trial as 
antiangiogenic molecule for the treatment of glioblastoma by inhibiting angiogenesis.  
Biological assays experienced that the Cilengitide, although not able to discriminate 
between αvβ3 and αvβ5 shows a higher affinity for αvβ3 respect with αvβ5 (IC50 = 
3.2 nM and 1.7 nM respectively) ( Liu Z., et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10  Cilengitide structure 
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In 2003 was developed the molecule S247, a peptidomimetic compound able to bind 
αvβ3 integrin with high affinity (IC50= 0.4nM) and that was demonstrated  both in vitro 
and in vivo that decreases colon cancer metastasis and angiogenesis (Reinmuth N., 
et al., 2003).  
In 2004 Lark and co-workers designed and characterized a new orally active Arg-Gly-
Asp peptidomimetic vitronectin receptor antagonist named SB 265123 for prevention 
of bone loss in osteoporosis. Even if, SB 265123 inhibits αvβ3-mediated cell 
adhesion with an IC50 =60 nM, the compound binds both αvβ3 and the closely related 
integrin αvβ5 with high affinity (Ki 3.5 and 1.3 nM, respectively), moreover binds, 
even if weakly, to the related RGD-binding integrins αIIbβ3 (Ki >1 µM) and α5β1 (Ki 
>1 µM) (Lark M.W., et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
Moreover, Scolastico  and co-workers in 2006 have synthesised a small library of 
cyclic RGD pentapeptide mimics incorporating stereoisomeric 5,6- and 5,7-fused 
bicyclic lactams some of them are reported in (Figure12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In 2009 the same team developed cyclic RGD-containing azabicycloalkane peptides 
(Figure 13A), and amide and ester derivative of these compunds suitable for target 
drug delivery and diagnostic applications (Figure 13B).  
Fig. 12  Cyclic RGD pentapeptide mimics cyclo(Arg-Gly-Asp-Lactam) 1–7. The ring size and the 
stereochemistry at the bridgehead (cis or trans) and at the C3 (S or R) carbon of the bicyclic 
lactam are reported in parentheses ( Belvisi L., et al., 2006). 
 
Fig. 11 SB 265123 structure ((Lark M. W., et al., 2004). 
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These molecules shown have a major affinity for target integrins, compared with the 
ligands of first generation reported above (IC50 of 53.7nM and between 30 and 
100µM respectively) (Manzoni L., et al., 2009). 
 
 
 
 
Another interesting application of αvβ3 ligands is in diagnostic field.  
In the last years, the development of radiolabelled peptides for imaging of a variety of 
tumours, infection/inflammation and thrombus has seen a new era in nuclear 
medicine. Due to their small size, peptide molecules exhibit favourable 
pharmacokinetic characteristics, such as rapid uptake in target tissue and rapid blood 
clearance, which potentially allow images to be acquired at ones after the 
administration of the radioactive compounds.  
In this contest, radiolabeled cRGD peptides in combination with nuclear imaging 
techniques such as positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) have been extensively studied for imaging of αvβ3 
expression in experimental tumours (Dijkgraaf I., et al., 2010).  
Furthermore in the field of angiogenic research, non-invasive monitoring of molecular 
processes in the angiogenic cascade will be of great interest for investigation on the 
mechanisms of angiogenesis basic science, as well as clinical settings where it could 
help in planning and controlling antiangiogenic therapies.  
The lead compound in this field is the radiolabeled Cilengitide’s analogue, developed 
by Kessler and co-workers in 2001, shown in figure 14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13 Synthesis of pseudopeptides based on azabicycloalkane scaffold (A). Synthesis of the 
amide derivatives 42–44 and ester 45 (B) (Manzoni L., et al., 2009). 
 
Fig.14 Schematic structure of [
18
F]Galacto-RGD 
(Haubner R., et al., 2001). 
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It was obtained through 18F-labeling of the RGD-containing glycopeptide cyclo(-Arg-
Gly-Asp-DPhe-Lys(sugar amino acid)-) with 4-nitrophenyl 2-[18F]fluoropropionate. 
The obtained compound was biologically evaluated. In particular in vitro binding 
assays showed that the inhibitory peptide was able to fully suppress the binding of 
the ligands (vitronectin or fibrinogen) to the isolated immobilized receptors (αIIbβ3, 
αvβ5, and αvβ3) and that the binding kinetics followed a classic sigmoid path.  
The IC50s of [
18F]Galacto-RGD were 5 (αvβ3), 1.000 (αvβ5), and 200-1200-fold 
higher affinity for αvβ3 than for αvβ5 and aIIbb3,respectively. 
Other interesting compounds was synthesised using [18F]Galacto-RGD, a 
glycosylated cyclic pentapeptide with the sequence cyclo(-Arg-Gly-Asp-DPhe- 
Lys(SAA)-) (SAA=sugar amino acid) developed to permit a non-invasive 
determination of  αvβ3 integrin expression in vivo (Beer A.J., et al., 2008) (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The main drawback of all reported molecule is a low selectivity for αvβ3 although 
they show a high affinity for the receptor. To overcome this limit, in 2006 a new 
potent and selective peptide, named RGDechi, able to bind the integrin αvβ3 with a 
comparable affinity to Cilengitide but with improved selectivity was reported in 
literature (Del Gatto A., et al., 2006) (Figure 16). 
 
 
 
 
Fig. 15 Schematic structure of the radiolabelled DOTA-RGD 
peptides. Depending on the isotope used, the metal is 
hexacoordinated with pseudoctrahedral cis geometry (M=68Ga) or 
octacoordinated with twisted square antiprismatic coordination 
geometry (M=111In; as presented at the scheme) (Beer A.J., et 
al., 2008). 
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RGDechi was designed starting from the Cilengitie-avb3 complex structure. It is a 
chimeric bifunctional peptide, including a cyclic RGD pentapeptide covalently linked 
by an amino acidic spacer to the C-terminus domain of the Echistatin, a natural 
antagonist of αvβ3 integrin extracted from the venom of the snake Echis Carinatus. In 
vitro and in vivo studies demonstrated that RGDechi is able to discriminate between 
αvβ3, αvβ5 and αIIbβ3 (Del Gatto A., et al., 2006). Considering the advantages of the 
radiolabeled peptides application in diagnostic field and the high selectivity of 
RGDechi peptide, the same research group designed and synthesised an RGDechi 
analogue suitable for diagnostic and therapeutic applications, named RGDechiHCit 
(Figure 17) (Zannetti A., et al., 2009). RGDechiHCit presents a residue of 
homocitrulline, an unnatural amino acid residue related to lysine, in substitution of the 
Lys1 of RGDechi peptide to permit the selective labelling of the lysine at the cyclic 
portion. PET and SPECT imaging in vivo studies confirmed that the peptide 
selectively  localizes on αvβ3 expressing tumor cells in xenograft animal model 
(Zannetti A., et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Echistatin  
C-Terminal 
Linker 
RGDeK 
Fig.17 RGDechiHCit peptide (Zannetti A., et al., 2009). 
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Fig. 16 RGDechi pepide (Del Gatto A., et al., 2006) 
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1.3.2 αvβ3 integrin: ligands for drug delivery systems 
 
Recenly, an explosive development of vectors (i.e. micelles, liposomes, etc…) to 
improve the delivery of drug or tracers in targeted tissues has been reported in 
literature (Wu H.C.,  et al., 2010; Gao C.,et al., 2009). In particular, nanoparticles 
(NP)  are playing a pivotal role in providing new types of targeted delivery systems.  
Drug delivery based on NP consists of three essential molecules: 1) nanostructure as 
vehicle; 2) drug conjugated to the nanoparticles; 3) ligands linked to the 
nanoparticles which binds with high affinity target cells. 
Several peptides was used as ligands to obtain selective nanosystems suitable for 
therapeutic and diagnostic applications.  
In 2006 Winter at al. developed αvβ3 integrin-targeted paramagnetic nanoparticles 
functionalised with Fumagillin, a natural antimicrobic and antiangiogenic biomolecule, 
that inhibit angiogenesis in atherosclerosis animal model (hyperlipidemic rabbit) and 
are suitable for MRI (magnetic resonance imaging) (Winter P.M.,  et al., 2006). 
Moreover, in 2007 Lesniak et al., synthesized a stable and clinically relevant 
dendrimer based nanodevice (ND) cRGD-BT(biotine)-ND that exhibits superior 
binding to the αvβ3 integrin, when either compared to the same free cRGD peptide or 
to the biotinylated nanodevice without covalently attached peptide (Lesniak W.G., et 
al., 2007). 
Likewise, in 2008 the synthesis of αvβ3 integrin targeted paramagnetic 
perfluorocarbon nanoparticle formulated to deliver selectively the rapamycin, 
an immunosuppressant drug used to prevent rejection in organ transplantation, was 
reported.  
Many biological studies have shown that this nanosystem prepared for diagnostic 
applications, also inhibits stenosis after balloon injury (Waters E. A., et al., 2008). 
Among nanostructured materials, gold nanoparticles (AuNP) also known as 
“nanogold” are particularly interesting for their intrinsic properties (Bhattacharya R., et 
al., 2007).  
Nanogold are aggregates of sub-micrometre-sized particles of gold (1-100nm) in a 
fluid, usually water with an unique optical propriety: the Plasmonic resonance. This 
physical effect is due to the resonant coupling of incident light to the collective 
oscillation mode of the conduction electrons in the noble metal nanoparticles and is 
responsible for the commonly observed enhancement in the optical absorption. It 
may also accompany a strong scattering as a secondary process, usually when the 
particle size is larger than a few tens of nanometers (Duncan B., et al., 2010). The 
magnitude of the scattering efficiency and the relative contribution to the total 
extinction have been shown to vary with the particle size and shape, metal 
composition, and surrounding medium. The optical scattering is useful in imaging 
methods to detect conjugated biosystems and has been used in the diagnostics of 
cancer cells (Melancon M., et al., 2009). For small particles, optical absorption has a 
dominant effect and the absorbed light energy generally undergoes a thermal 
dissipation process giving rise to localized heat, which constitutes a basis of 
biomedical therapeutic applications.  
Gold nanoparticles presents many other advantages. They are inert and non toxic, 
have low immunogenicity,  can be easily synthesised in different sizes ranging from 
1 nm to 150 nm and ready functionalized generally through thiol linkages. Moreover, 
their photophysical properties could trigger drug release at remote place (Ghosh P., 
et al., 2008).  
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However, nanogold present also a relevant limit: they are not stable in solution and 
so tend to give aggregates. To prevent the particles from aggregating, some sort of 
stabilizing agents that cover the nanoparticle surface (Rautaray D., et al., 2004). 
Moreover, it is known that gold nanoparticles can be functionalised with various 
organic ligands to create organic-inorganic hybrids with advanced functionality. For 
example, the use of peptide sequences based on the GC repeats as stabilizing 
agents for the preparation of monolayer gold nanoparticles was recently reported in 
literature (Krpetić Z., 2009). 
Controlling the surface chemical composition and mastering its modification at the 
nanometer scale are critical issues for high-added value applications involving 
nanoparticles. The creation of specific surface sites on nanoparticles for selective 
attachment of ligand as targeting agents able to recognize tumor molecular markers 
is considered a promising starting point for their applications in the field of drug 
delivery. The repertoire of molecules that can be used as targeting agents is greatly 
expanded, since many ligands (antibody, peptides, proteins etc...) can be anchored 
on nanoparticles to create higher affinity via multivalent binding to tumor biomarkers. 
This capped system can be considered a good scaffold for functionalization of 
molecules suitable for tumour selective targeting delivery.  
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1.4 THE  AIM OF THE WORK 
 
In the last decade, αvβ3 integrin, due to its main role in many pathologies such as 
tumour angiogenesis, focused the attention of the scientific community as interesting 
target for development of new and selective systems for biotechnological 
applications. However, even if all v 3 ligands reported in the literature have  a good  
affinity for this receptor, they present a low selectivity and bind, even if with lower 
affinity, also other integrin receptors structurally homologues of v 3 such as v 5 
integrin (Smith J.W., et al., 2003; Eskens F.A., et al. 2003). Only recently, a  cyclic 
peptide named  RGDechiHCit, able to bind with high affinity and selectivity αvβ3 
integrin overexpressed on tumor cells was reported in literature (Del Gatto, 2006 
Zannetti A., al., 2009). Since no information was available about the antiangiogenic 
activity of this peptide, a first aims of this PhD thesis have been the study of 
RGDechiHCit effect on neovascularisation process (in collaboration with the 
department of clinic medicine, cardiovascular ad immunological science, University  
"Federico II" of Naples Italy) and study the degradation of this molecule in serum to 
solve this issue and evaluate the biotechnological application of this molecule as 
antagonist of αvβ3 integrin. 
αvβ3 integrin represents a great challenge also in the field of nanotechnologies for 
development of selective drug delivery systems. So a further object of this work has 
been the design and synthesis of a new peptide encompassing the RGD motif, 
critical for a selective binding of αvβ3 integrin, for gold nanoparticles (AuNP) delivery. 
Subsequently, we characterised both the RGD peptide and the targeted gold 
nanoparticles by spectroscopic techniques. The ability of RGD containing 
nanosystem in comparison with non functionalized NP to penetrate inside 
glioblastoma target cells was also tested. 
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2 MATERIALS AND METHODS 
 
2.1  MATERIALS 
 
Polypropylene reaction vessels and sintered polyethylene frits were supplied by 
Alltech Italia. F=DPhe amino acid, MeIm, TFA and scavengers were purchased from 
Fluka; Novasyn TGA, Novasyn TGR and 2-Chlorotrityl chloride resin, coupling 
reagents and all amino acids were from Novabiochem. DIPEA was purchased from 
Romil; piperidine from Biosolve; PhSiH3 and Pd(PPh3)4 from Sigma-Adrich. 
 
2.2 PEPTIDE SYNTHESIS 
 
2.2.1 RGDechiHCit synthesis 
 
The RGDechiHCit linear precursor with amino acidic sequence,  
H-KRGDeMDDPGRNPHHCitGPAT-OH, was synthesised using the Fmoc solid-
phase strategy (0.1 mmol) (Figure 18). The synthesis was carried out using all 
standard amino acids except for Fmoc-D-Glu-OAll, to insert the D-Glu residue in the 
peptide sequence by its carboxyl side chain and the Fmoc-HCit to functionalise 
selectively the Lys1 of peptide for therapeutic and diagnostics applications. 
The first amino acid was bound to the resin by treatment with Fmoc-Thr(tBu)-OH (5 
equiv.)/MSNT (5equiv.)/MeIm (3.75 equiv.) in DCM for 3 h. 
The Fmoc deprotection step was performed with 30% piperidine in DMF for 10 min 
and active ester-coupling reactions were carried out under a 10-fold excess of amino 
acid and  HBTU (9.8 equiv.)/HOBT (9.8 equiv.)/DIPEA (20 equiv.) in DMF.  
 
Fig 18 RGDechiHCit linear precursor 
 
During the RGDechiHCit synthesis, before the Fmoc deprotection of Lys1, a selective 
alpha-carboxyl deprotection of the D-Glu residue from the allyl group was carried out 
by treatment of the peptidyl resin with PhSiH3 (24equiv.)/Pd(PPh3)4 (0.25equiv.) in 
DCM (Figure 19).   
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Fig 19 RGDechiHCit linear precursor selective allylic group remotion (A). Fmoc Lys
1
deprotection (B). 
 
The final cyclization between αNH of Lys and αCO of D-Glu was performed on solid 
phase with PyBop (1.5equiv.)/HOBT(1.5equiv.)/DIPEA (2equiv.) in DMF (Figure 20) 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Fig 20 RGDechiHCit cyclisation scheme. 
 
 
 
 
B 
A 
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The peptide were cleaved off from the resin  and deprotected using a mixture of TFA/ 
H2O /EDT/TIS (94:2.5:2.5:1 v/v/v/v).  
The resin was filtered, and the peptide was precipitated using cold anhydrous diethyl 
ether. The crude product was purified by preparative RP-HPLC on the Shimadzu LC-
8A system, equipped  with an UV-Vis detector SPD-10A using a Phenomenex C18 
column (21 x 250 mm; 15µm; 300 Ǻ) and  a linear gradient of H2O (0.1%TFA)/CH3CN 
(0.1%TFA) from 5 to 70% of CH3CN (0.1%TFA) in 30 min at flow rate of 20ml/min. 
The purified peptide was characterized using LC-MS (Finnigan Surveyor MSQ) using 
a Phenomenex Jupiter Proteo C12 column (150x 2.00 mm; 4μm; 90Ǻ). The method 
developed at 0.2mL/min with a linear gradient of H2O 0.05% TFA/ CH3CN 0.05% 
TFA, from 5% to 70% for 30 min.  
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2.2.2 c(RGDf[NMe]V) synthesis  
 
The synthesis of the Cilengitide (0.1 mmol), (RGDf[NMe]V), was performed using the 
Fmoc chemistry and the 2-Chlorotrityl chloride resin as solid support. The resin 
loading was reduced from 1.16 mmol/g to 0.26 mmol/g by MeOH (4ml for 2 minutes) 
to prevent inter peptides cyclization side reactions. The linear protected peptide was 
assembled with the Gly residue at the C-terminus to prevent racemisation and steric 
hindrance during the cyclization step (Dechantsreiter M.A., et al., 1999). The first 
amino acid (1 eqiv.) was dissolved in dry THF (approx. 5 ml). The mixtrure was 
added to the resin and was stirred for 120 min.  At the end of this time, the resin was 
washed 3 times with DCM /MeOH/DIPEA (17:2:1 v/v/v); DCM (3x1min); 
DMF(3x1min); DCM (2x1min). The Fmoc deprotection step was performed with 30% 
piperidine in DMF for 10 min and active ester-coupling reactions were carried out 
under a 10-fold excess of amino acid and  HBTU (9.8 equiv.)/HOBT (9.8 
equiv.)/DIPEA (20 equiv.) in DMF (Figure 21). 
 
 
Fig 21 Cilengitide cyclisation scheme. 
 
At the end of the synthesis, the protected peptide was cleved from the resin using 
diluite TFA (1%) in DCM. The mixture was added to the solid support and was 
shaked for 2 minutes. The solution was filters by appling nitrogen pressure into a 
flask containing 10% pyridine in methanol (2 ml). This step was repeated for 10 times 
and at the end, the residual protected peptide was washed out from the resin with 
3x30 ml DCM, 3x30 ml MeOH, and the filtrates were analysed by TLC.  
Then, the filtrates containing the product were combined and and evaporated under 
reduced pressure to 5% of the volume. Finally, was added water (40 ml) to the 
residue and the mixture obtained was cooled with ice to aid precipitation of the 
product.  
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This last, was isolated by filtration through a sintered glass funnel and was dryed in 
an desiccator.  
At this point, the protected peptide was cyclisated in solution (1.25 x 10-3M) in DMF 
via in situ activation using PyBop, HOBt and DIPEA (1.5/1.5/2 eqiv) as cyclisation 
reagents. 
Final deprotection was achieved with TFA using a mixture of TFA/ H2O /EDT/TIS 
(94:2.5:2.5:1 v/v/v/v). The crude product was purified by preparative RP-HPLC on the 
Shimadzu LC-8A system, equipped  with an UV-Vis detector SPD-10A using a 
Phenomenex C18 column (21 x 250 mm; 15µm; 300 Ǻ) and  a linear gradient of H2O 
(0.1%TFA)/CH3CN (0.1%TFA) from 5 to 70% of CH3CN (0.1%TFA) in 30 min at flow 
rate of 20ml/min. The purified peptide was characterized by LC-MS (Finnigan 
Surveyor MSQ) using a Phenomenex Jupiter Proteo C12 column (150x 2.00 mm; 
4μm; 90Ǻ). The method developed at 0.2mL/min with a linear gradient of H2O 0.05% 
TFA / CH3CN 0.05% TFA from 5% to 70% for 30 min.  
 
2.3 In vitro STUDIES 
 
All in vitro studies were performed using bovine aortic EC (BAEC) and vascular 
smooth muscle cells (VSMC) cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Sigma-Aldrich, Milano, Italy) as previously described and validate (Iaccarino 
G., et al., 2004). All experiments were performed in triplicate. 
 
2.3.1 Cell proliferation assay 
 
Cells were seeded at density of 10000 per well in six-well plates, serum starved, pre-
incubated overnight with c(RGDf-[NMe]V), or RGDechiHCit (10-6M) and then 
stimulated with 5% fetal bovine serum (FBS). Cell number was measured at 3, 6, 12, 
24 h after stimulation as previously described (Santulli G., et al., 2009). 
 
2.3.2 DNA synthesis 
 
Cells were serum-starved for 24 h and then incubated in DMEM with [3H]thymidine 
and 5% FBS. After 3, 6, 12, 24 h [3H]thymidine incorporation was assessed as 
previously described (Santulli G., et al., 2009). 
 
2.3.3 Endothelial Matrigel assay 
 
The formation of network-like structures by EC on Matrigel® (BD Biosciences, 
Bedford, MA, USA) was performed as previously described and validated (Santulli 
G., et al., 2009). 
Tubule formation was defined as a structure exhibiting a length four times its width. 
Network formation was observed using an inverted phase-contrast microscope 
(Zeiss). As negative control Phenylephrine (10-7M) was used. Representative fields 
were taken, and the average of the total number of complete tubes formed by cells 
was counted in 15 random fields by two independent investigators. 
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2.3.4 Western blot 
 
Immunoblot analyses were performed as previously described and validated (Illario 
M., et al., 2005). 
Serine-tyrosine phosphorylated ERK1/2 (extracellular signal regulated kinase; Cell 
Signaling Technology, Danvers, MA, USA), total ERK (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), pCaMKII (Santa Cruz Biotechnology), CaMKII (Santa Cruz 
Biotechnology) were visualized with specific antibodies, anti-rabbit and anti-goat 
horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology) 
and standard chemiluminescence (Pierce) on autoradiographic films. 
Autoradiographies were then digitalized and densitometry quantification performed 
using dedicated software (ImageQuaNT; Molecular Dynamics). Levels of VEGF, 
were determined by immunoprecipitation of VEGF (protein A/G agarose beads 
conjugated with a rabbit polyclonal antibody raised against VEGF (Santa Cruz 
Biotechnology) visualized by a goat polyclonal IgG (Santa Cruz Biotechnology). 
Experiments were performed in triplicate to ensure reproducibility. Data are 
presented as arbitrary densitometry units after normalization for the total 
corresponding protein or actin as internal control (Ciccarelli M., et al., 2008). 
 
2.3.5 Peptides processing in serum and plasma 
 
About 8 μl of a 1 mg/ml solution of RGDechiHCit peptide and of Cilengitide were 
incubated at 37° C with 20 μl human serum and plasma. Samples withdrawn after 1, 
2, 4 and 24 h were, centrifuged for 1 min at 10,000 × g ( Bracci L., et al., 2003).  
These solutions were analyzed by LC-MS using a Phenomenex C18 column (250x 2 
mm; 5 µm; 300 Ǻ) and  a linear gradient of H2O (0.05%TFA)/CH3CN (0.05%TFA) 
from 10% to 80% of CH3CN in 30 min at flow rate of 0.2 ml/min. 
 
2.4 In vivo STUDIES 
 
2.4.1 Wound Healing 
 
Wound healing assay was performed on 14-week-old (weight 293±21ag) 
normotensive WKY male rats (Charles River Laboratories, Milan, Italy; n=18), and 
Matrigel plugs experiments were carried out on 16-week-old (weight 33±4 g) c57BL/6 
mice (Charles River Laboratories, Milan, Italy; n=13). All animal procedures were 
performed in accordance with the Guide for the Care and Use of Laboratory Animals 
published by the National Institutes of Health in the United States (NIH Publication 
No. 85- 23, revised 1996) and approved by the Ethics Committee for the Use of 
Animals in Research of “Federico II” University (Illario M, et al., 2005). 
The rats (n=18) were anesthetized using vaporized isoflurane (4%, Abbott) and 
maintained by mask ventilation (isoflurane 1.8%). The dorsum was shaved by 
applying a depilatory creme (Veet, Reckitt-Benckiser, Milano, Italy) and disinfected 
with povidone iodine scrub. A 20 mm diameter open wound was excised through the 
entire thickness of the skin, including the panniculus carnosus layer, as described 
and validated [5, 26]. Pluronic gel (30%) containing (10-6 M) c(RGDf-[NMe]V) (n=6), 
RGDechiHCit (n=7), or saline (n=5) was placed directly onto open wounds, then 
covered with a sterile dressing. Two operators blinded to the identity of the sample 
measured wound areas every day, for 8 days. Direct measurements of wound region 
were determined by digital planimetry (pixel area), and subsequent analysis was 
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performed using a computer-assisted image analyzer (ImageJ software, version 
1.41, National Institutes of Health, Bethesda, MD, USA). Wound healing was 
quantified as a percentage of the original injury size. After eight days, rats were 
euthanized and dorsal skin was collected, fixed by immersion in phosphate buffered 
saline (PBS, 0.01M, pH 7.2-7.4)/formalin and then embedded in paraffin to be 
processed for immunohistology, as described (Takahashi S.,et al., 2010). 
 
2.4.2 Matrigel Plugs 
 
Mice (n=13), anesthetized as described above, were injected subcutaneously 
midway on the dorsal side, using sterile conditions, with 0.2 ml of Matrigel® (BD 
Biosciences, Bedford, MA, USA), mixed with 10-6M VEGF and 10-5M c(RGDf-
[NMe]V) (n=4), 10-6M VEGF and 10-5M RGDechiHCit (n=5), or 10-6M VEGF alone 
(n=4). After seven days, mice were euthanized and the implants were isolated along 
with adjacent skin to be fixed in 10% neutral-buffered formalin solution and then 
embedded in paraffin. All tissues were cut in 5 μm sections and slides were 
counterstained with a standard mixture of hematoxylin and eosin. Quantitative 
analysis was done by counting the total number of endothelial cells, identified by 
lectin staining, as previously described (Takahashi S., et al., 2010) in the Matrigel 
plug in each of 20 randomly chosen cross-sections per each group, at ×40 
magnification, using digitized representative high resolution photographic images, 
with a dedicated software (Image Pro Plus; Media Cybernetics, Bethesda, MD, USA). 
 
2.5 DATA PRESENTATION AND STATISTICAL ANALYSIS  
 
All data are presented as the mean value±SEM. Statistical differences were 
determined by one-way or two-way ANOVA and Bonferroni post hoc testing was 
performed where applicable.  
A p value less than 0.05 was considered to be significant. All the statistical analysis 
and the evaluation of data were performed using GraphPad Prism version 5.01 
(GraphPad Software, San Diego, CA, USA). 
 
2.6 FUNCTIONALISED GOLD NANOPARTICLES 
 
2.6.1 RGD(GGC)2, RGD(GC)2 and (GC)2 design and synthesis  
 
The peptides RGD(GGC)2, RGD(GC)2, and (GC)2 were synthesized using the Fmoc 
solid-phase strategy (0.1 mmol) using all standard amino acids except for Fmoc-Glu-
OAll. Peptide sequences are reported in Table 3.  
 
Peptide Sequence 
RGD(GGC)2 c(RGDfE)GGCGGCG-NH2 
RGD(GC)2 c(RGDfE)AGCGGCG-NH2 
(GC)2 Ac-GGCGGCG-NH2 
 
TAB. 3  RGD(GGC)2; RGD(GC)2; (GC)2 sequences 
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Active ester-coupling reactions were carried out under a 5-fold excess of amino acid, 
incused the first residue of Gly, and  HBTU (9.8 equiv.)/HOBT (9.8 equiv.)/DIPEA (20 
equiv.) in DMF.  
The Cyst residues, 5-fold excess, was coupled without preactivation using 
HBTU/TMP(5eqiv./5eqiv.) for 90 min to prevent racemisation (Han Y., et al.,1997). 
The Fmoc deprotection step was performed with 30% piperidine in DMF for 10 min 
and. During the synthesis, before the Fmoc deprotection of the last amino acid, a 
selective deprotection of the Glu residue from the allyl group was carried out by 
treatment of the peptidyl resins with PhSiH3 (24equiv.)/Pd(PPh3)4 (0.25equiv.) in 
DCM Figure 22 A). The final cyclization between αNH of Arg and αCO of D-Glu was 
performed on solid phase with PyBop, HOBt and DIPEA (1.5/1.5/2 eqiv.) as 
cyclisation reagents (Figure 22 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               
 
 
 
 
Fig. 21  RGD(GGC)2 deallylation scheme (A); RGD(GGC)2 cyclisation scheme(B). 
 A 
B 
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N-terminal acetylation of the peptide (GC)2 was carried out with a mixture of acetic 
anhydride/DIPEA/ HOBT (0.5M/0.5M/0.125M) in DMF two times for 10 min.  
All the peptides were cleaved off from the resin and deprotected using a mixture of 
TFA/ H2O /EDT/TIS (94:2.5:2.5:1 v/v/v/v).  
The resins were filtered, and the peptide was precipitated using cold anhydrous 
diethyl ether. The crude products were purified by preparative RP-HPLC on the 
Shimadzu LC-8A system, equipped  with an UV-Vis detector SPD-10A using a 
Phenomenex C18 column (21 x 250 mm; 15µm; 300 Ǻ) and  a linear gradient of H2O 
(0.1%TFA)/CH3CN (0.1%TFA) from 5 to 70% of CH3CN (0.1%TFA) in 30 min at flow 
rate of 20ml/min. The purified peptides were characterized using LC-MS (Finnigan 
LCQ DECA XP MAX) using a Phenomenex Jupiter Proteo C12 column (150x 2.00 
mm; 4μm; 90Ǻ). The method developed at 0.2mL/min with a linear gradient of H2O 
0.05% TFA/ CH3CN 0.05% TFA, from 5% to 70% of CH3CN for 30 min.  
 
2.6.2 Preparation of functionalized gold nanoparticles 
 
For preparation of RGD(GC)2 and (GC)2 functionalised gold nanoparticles (named 
RGD(GC)2AuNPs and(GC)2AuNPs respectively) an aqueous solution of NaAuCl4 
(5∙10-2M) and proper volumes of the corresponding peptide aqueous solution (5∙10-
4M) were mixed in six test-tubes containing 5 mL of H2O mQ, under vigorous 
magnetic stirring. Au:stabiliser peptide:agent molar ratios have been carefully set up 
following the quantities and molar ratios reported in table 4. 
 
 
 
 
 
 
 
 
 
 
 
TAB. 4  Peptide quantities and molar ratios 
 
For setting the minimal amount of the needed peptide for an efficient stabilization of 
Au nanoparticles, series of probes have been carried out varying the molar ratio of 
peptide: metallic Au. Aqueous solution of NaAuCl4 (52 μL, C= 4.64∙10
-2M and 47 μL, 
C= 5.07∙10-2M) and the corresponding volumes of the peptide aqueous solutions 
were added in six test-tubes containing 5 mL of mQ water under vigorous stirring 
(Porta F., et al., 2008). An aqueous solution of NaBH4 0.1M (5∙10
-3 mmol) was used 
as reducing agent and it was added after 5 min from the previous addition. Colourful 
sols were immediately formed. The colours of the obtained sols varied from bluish to 
red depending on the molar ratio from the component 
 
 
 
 
 
 
№ n (mmol) Volume (μL) Molar ratios 
(Au:L:BH4
-) 
1 2.4∙10-5 27.9 1:0.01:2 
2 1.2∙10-5 14 1:0.005:2 
3 2.4∙10-6         2.8 1:0.001:2 
4 2.4∙10-5 28 1:0.01:1 
5 1.2∙10-5 14 1:0.005:1 
6 2.4∙10-6 2.8 1:0.001:1 
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2.6.3 UV characterization 
 
The peptides and the functionalised gold nanoparticles UV-VIS characterisation was 
performed using a spettrophotometer Jasco V550 and standard UV-VIS quartz 
cuvettes (Hellman) with a 1cm path length and a volume of 500 μl. The data were 
collected with a speed scan of 100nm/min and data pitch of 1nm.  
The samples were prepared by dissolving the compounds to a concentration of 1.8 x 
10-5M in H2O. The spectra were acquired  in the range of  200-800nm. 
 
2.6.4 ATR-FTIR characterization 
 
 ATR-FTIR analysis was performed on a JASCO FT/IR-4100 spectrometer from 2300 
to 500 cm-1. For the ATR-FTIR analysis, the samples of gold colloids were freeze-
dried, and the analysis of the free peptide and RGD(GC)2 stabilized gold particles 
was performed on solid state.  
  
2.6.5 NMR characterization 
 
NMR samples consist of 1 mg of RGD peptide or 0.5 mg of RGD(GC)2AuNPs 
nanoparticles and (GC)2 nanoparticles dissolved in 600 µl of a H2O/D2O (90:10) 
mixture. NMR spectra for resonance assignments of the RGD peptide were collected 
at 25°C on a Varian UNITYINOVA 600 spectrometer, equipped with a 5-mm triple 
resonance probe and triple-axis pulsed-field gradients, located at the “Institute of 
Biostructures and Bioimaging” (CNR, Naples, Italy). Proton resonances were  
assigned using a standard protocol based on comparison of 2D [1H, 1H] TOCSY 
(Griesinger et al 1988) (mixing time: 70 ms) and 2D [1H, 1H] ROESY (Bax and Davis, 
1985) (mixing times: 150 and 200 ms) experiments. 2D spectra were generally 
recorded with 64 scans, 256 FIDs in t1, 2048 data points in t2.  
NMR spectra (1D proton and 2D [1H, 1H]  TOCSY (70 ms mixing time)) of a 
dispersion of RGD(GC)2AuNPs and (GC)2AuNPs were recorded on the Varian 
UNITYINOVA 600 spectrometer equipped with a cold probe, by acquiring 512-2048 
and 256 scans for 1D and 2D experiments respectively. 
Water signal was suppressed by means of either the WATERGATE PFG (Piotto et al 
1992) or the DPFGSE (Double Pulsed Field Gradient Selective Echo) techniques 
(Dalvit, 1998). Proton resonances were referenced to the water signal at 4.75 ppm. 
Spectra were processed with the Varian software VNMRJ 1.1D and analyzed with 
NEASY (Bartels et al 1995) as implemented in CARA. 
 
2.6.6 TEM characterization 
 
Transmission electron microscopy (TEM) micrographs of the colloidal dispersions 
were obtained using a FEI Tecnai Spirit instrument operated at an accelerating 
voltage of 120 kV. 
Carbon-supported copper grids were used to support the colloidal dispersions. 
Specimens for imaging by TEM were prepared by evaporating a droplet (100ul) of 
gold nanoparticle solutions (8x10-5M) onto carbon-coated copper grids. A histogram 
of the particle size distribution and the average particle diameter were obtained by 
measuring about 200 particles (Porta F., et al., 2008).  
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2.6.7 Cellular uptake 
 
For cellular uptake studies, U-87 MG cells have been used, kindly donated by Dr. 
Maura Francolini of the Dept. of Pharmacology, Chemotherapy and Medical 
Toxicology of Milan, Italy. Glioblastoma is the highest differentiated form of astrocytic 
brain tumors; in most cases it is irresponsive to radiation and chemotherapy. U-87 
MG (malignant glioma) cells are used as an vitro model of human glioblastoma cells 
to investigate the cytotoxic effect of chemo-therapeutic drugs towards cancer cells.  
Cells were grown on coverslip in Dulbecco's modified Eagle's medium (Gibco, 
Paisley, Scotland) supplemented with 10% heat-inactivated foetal calf serum (Gibco), 
1% L-glutamine (Eurobio), 100 UI/ml penicillin G and 100 g/ml streptomycin and 
maintained at 37°C in a humid atmosphere of 5% CO2 in air. After treatment with 
2x10-3M of AuRGD for 5, 20, 60, 120, and 180 min the supernatant was removed, 
and sprayed with CryoSpray® in order to fix the cells. Subsequently, a cover glass 
slide with fixed cells was placed onto a microscopy glass slide containing 10 l of Gel 
Mount® aqueous-based mounting medium. Prepared glass slides were glued and 
kept in freezer/dark room before microscopy observations. In the described protocol, 
use of 4% paraformaldehyde or glutharaldeide fixative solution is avoided in order to 
remove any false signals during confocal microscopy observations (Krpetić Z, et 
al.,2009). 
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3 RESULTS AND DISCUSSION  
 
3.1 PEPTIDES: DESIGN, SYNTHESIS AND CHARACTERISATION  
 
3.1.1 Synthesis and Characterization of RGDechiHCit 
 
The peptide RGDechiHCit was designed on the bases of the RGDechi peptide (Del 
Gatto A., et al., 2006). 
It presents a residue of homocitrulline, an unnatural amino acid residue related to 
lysine, in substitution of the Lys1. 
RGDechiHCit was synthesised on solid phase using the Fmoc chemistry as 
previously described. On solid phase cyclisation step was optimised using a minor 
dilution (2x10-4M) compared with which reported in literature (Del Gatto A., et al., 
2006) and was obtained with a yield of 30% and a purity of 99%. 
The purified peptide (theoretical MW=2100.1 Da) was characterized using LC-MS, 
which gave the expected molecular ion peak [M + H]+ of 2100.3 and an ion [M+ 
2H]+2of 1050 respectively as showed in figure 23  A and B. 
 
 
Fig. 23  RGDechiHCit eptide mass spectrum (A); TIC profile and HPLC spectrum (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1051.3 
701.3 
[M+2H]2+ 
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3.1.2 Synthesis and Characterization of c(RGDf[NMe]V) 
 
To have a peptide as positive control in RGDechiHCit biological studies, we 
synthesised the Cilengitide, having sequence c(RGDf[NMe]V). 
Its synthesis was performed on liquid phase as previously described. The peptide 
was obtained with a final yeald of 49% and a purity of 99%. The purified peptide  
(theoretical MW=589 Da) was characterized by LC-MS, which gave the expected 
molecular ion peak [M + H]+ of 589 as showed in figure 24A and B. 
 
 
 
Fig. 24 c(RGDf[NMe]V) peptide mass spectrum (A); TIC profile and HPLC spectrum (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B [M+H]+ 
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3.2 PEPTIDES IN SERUM STABILITY EVALUATION  
 
RGDechiHCit and c(RGDf[NMe]V) peptides stabilities were evaluated in serum. The 
degradation of the peptides were followed by LC/MS. The reversed-phase high 
performance liquid chromatography (RP-HPLC) of RGDechiHCit before the serum 
incubation showed a single peak at tr=11.82 min corresponding to the complete 
sequence (theoretical MW=2100.1 Da) as indicated by the [M+H]+, [M+2H]2+ and 
[M+3H]+3 molecular ion adducts in the MS spectrum (Figure 25A). After 1h, 
chromatography showed two peaks, ascribable to RGDechiHCit and to a fragment of 
the complete sequence (theoretical MW=1929.1Da), respectively, as confirmed by 
MS spectrum. Finally, after 24h a further peak at tr=10.93 min corresponding to 
another RGDechiHCit degradation product (theoretical MW=1775.8 Da) appeared, as 
indicated by the molecular ion adducts in the MS spectrum, although the peaks 
attributed to the RGDechiHCit and to the first fragment were still present (Figure 25 
B). Considering the obtained fragment we hypothesized that RGDechiHCit peptide 
was cleaved by a Prolyl peptidase: a serine protease subfamily that cleaves peptide 
bonds at the C-terminal side of proline residues. Its activity is confined to action on 
oligopeptides of less than 10 kDa. 
 
 
Fig. 25: RGDechiHCit after incubation in human serum at t=0 (A) and after 24h (B). 
 
 
 
 
40 
 
In contrast with RGDechiHCit, c(RGDf[NMe]V) showed high stability in serum. The 
RP-HPLC profile of the peptide before the incubation showed a single peak at 
tr=16.64 min, ascribable to the complete sequence by the MS spectrum (Figure 26A). 
After 24h of incubation chromatogram and mass profiles failed to identify any 
degradation product (Figure 26 B). 
 
 
Fig.  26 c(RGDf[NMe]V) after incubation in human serum at t=0 (A) and after 24h (B). 
 
Since RGDechiHCit showed a low stability, we replenished antagonists every six 
hours in experiments involving chronic exposure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
41 
 
3.3 RGDechiHCit  ANTIANGIOGENIC ACTIVITY: in vitro STUDIES 
 
3.3.1 Cell proliferation and DNA synthesis 
 
Angiogenesis is intimately associated to EC proliferation. Therefore, we explored the 
effects of RGDechiHCit and c(RGDf[NMe]V) on hFN-stimulated EC. In this cellular 
setting, after 6 hours, both αvβ3 integrin antagonists inhibited in a comparable way 
the ability of hFN to induce proliferation (hFN: +1.98±0.6; hFN+RGDechiHCit: 
+0.58±0.24; hFN+c(RGDf[NMe]V): +0.6±0.38 fold over basal; p<0.05, ANOVA) as 
depicted in figure 27A. After 20 hours such inhibitory effect was less marked (Figure 
27A). In VSMC there was only a trend of an anti-proliferative effect for these 
peptides, due to the less evident action of hFN in this specific cellular setting (hFN: 
+1.21±0.1; hFN+RGDechiHCit: +0.93±0.07; hFN+c(RGDf[NMe]V): +0.9±0.09 fold 
over basal; NS; Figure 27A). The effects of RGDechiHCit and c(RGDf[NMe]V) on EC 
and VSMC proliferation were also measured by assessing the incorporation of 
[3H]Thymidine in response to hFN.  
This assay confirmed the anti-proliferative action of both these peptides, which is 
more evident after 6 hours and in ECs (hFN: +1.84±0.24; hFN+RGDechiHCit: 
+1.02±0.2; hFN+c(RGDf[NMe]V): +1.09±0.07 fold over basal; p<0.05, ANOVA; 
Figure 27B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 27  In vitro effects of c(RGDf[NMe]V) and RGDechiHCit on cell proliferation (Panel A) and DNA 
synthesis assessed by [
3
H]thymidine incorporation (Panel B) in bovine aortic endothelial cells (EC). 
Given alone, c(RGDf[NMe]V) or RGDechiHCit did not affect EC proliferation. Neverteless, incubation 
with these V 3 integrin antagonists inhibited in a comparable way EC proliferation in response to the 
mitogenic stimulus, hFN. All experiments depicted in this figure were performed from three to six times 
in duplicate (*= p<0.05 vs Basal, #= p<0.05 vs hFN).  
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On the contrary, the effect of RGDechiHCit on VSMC did not reach statistical 
significance in comparison with the c(RGDf[NMe]V) used as control (Figure 28B). 
 
 
 
Fig. 28 In vitro effects of c(RGDf[NME]V) and RGDechiHCit on vascular smooth muscle cell (VSMC) 
cell proliferation (Panel A) and DNA synthesis assayed by [
3
H]thymidine incorporation (Panel B). In 
this cellular setting, hFN induced a mitogenic stimulus, appreciable especially at 20h. c(RGDf[NMe]V) 
but not RGDechiHCit at that time-point induced an attenuation of such proliferative response. All 
experiments were performed from three to five times in triplicate (*= p<0.05 vs Basal; #= p<0.05 vs 
hFN). 
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3.3.2 Effects on cellular signal transduction 
 
Since hFN-mediated activation of ERK2 is linked to angiogenesis (Eliceri B.P., et al., 
1998; Illario M., et al., 2005), we analyzed the ability of RGDechiHCit and 
c(RGDf[NMe]V) to inhibit hFN-induced phosphorylation of ERK2 in EC and VSMC. In 
accordance with the results on cell proliferation and [3H]Thymidine incorporation, in 
EC both RGDechiHCit and c(RGDf[NMe]V) significantly inhibited the hFN-induced 
phosphorylation of mitogen-activated protein ERK2 (Figure 29A). Also, in VSMC, 
there was no significant inhibition of ERK2 phosphorylation by the RGDechiHCit 
compund c(RGDf[NMe]V) (Figure 29B). 
 
 
 
Fig 29 Panel A: In vitro effects of c(RGDf[NMe]V) and RGDechiHCit on EC signal transduction. 
Extracellular signal regulated kinase (ERK)/mitogen-activated protein kinase activation: western blot of 
activated (phosphorylated: pERK) ERK2 after hFN-stimulation. Equal amounts of proteins were 
confirmed via blotting for total ERK. Densitometric analysis (bar graph) showed that hFN stimulation 
caused ERK activation (*= p<0.05 vs Basal) and that treatment with V 3 antagonists blunted such 
activation (#= p<0.05 vs hFN). Error bars show SEM. Representative blots are shown in the inset. In 
vitro effects of c(RGDf[NMe]V) and RGDechiHCit on VSMC signal transduction were represented in 
Panel B. Extracellular signal regulated kinase (ERK)/mitogen-activated protein kinase activation: 
western blot of activated (phosphorylated: pERK) ERK2 after hFN-stimulation. Blots were then 
stripped and reprobed for either total ERK as a loading control. Densitometric analysis (bar graph) 
showed that hFN induced ERK phosphorylation (*= p<0.05 vs Basal) and that treatment with 
c(RGDf[NMe]V) but not RGDechiHCit decreased such activation (#= p<0.05 vs hFN). Error bars show 
SEM. Representative blots are presented in the inset. 
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3.3.3 Evaluation of VEGF expression 
 
Angiogenesis is largely dependent on ERK2 activation, which in turn promotes 
cellular proliferation and expression of VEGF. This cytokine promotes infiltration of 
inflammatory cells, proliferation of ECs and VSMCs and sustains the proangiogenic 
phenotype (Mahabeleshwar G.H., et al., 2007). 
The early release (6 hours) of the cytokine is therefore an important readout when 
studying angiogenesis in vitro. On these grounds, we assessed the expression levels 
of this pivotal proangiogenetic factor in EC after 6 hours of stimulation with hFN. hFN 
induces VEGF release and such response was blunted by incubation with either 
integrin antagonist, as depicted in figure 30 (hFN: +18.9±1.02; hFN+RGDechiHCit: 
+2.44±0.76; hFN+c(RGDf[NMe]V): +3.19±0.73 fold over basal, ADU; p<0.05, 
ANOVA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 30  VEGF production in bovine aortic endothelial cells (ECs) measured by Western blot (inset). 
Shown are VEGF levels after 6 hours of serum starvation. Equal amount of proteins were verified by 
blotting for actin. Quantification of western blot from all experiments demonstrated that hFN was able 
to increase VEGF production (*= p<0.05 vs Basal), while after c(RGDf[NMe]V) or RGDechiHCit 
treatment VEGF levels returned to basal conditions (#= p<0.05 vs hFN). All data derived from three 
different experiments performed in duplicate. The results were expressed as fold increased with 
respect to the basal condition in untreated samples. Error bars show SEM 
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3.3.4 Endothelial Matrigel assay 
 
The formation of capillary-like tube structures in the ECM by ECs is a pivotal step in 
angiogenesis and is also involved in cell migration and invasion (Iaccarino G., et al., 
2005). To evaluate any potential antiangiogenic activity of our novel integrin 
antagonist, in vitro angiogenesis assays were conducted by evaluating hFN-induced 
angiogenesis of ECs on Matrigel. 
As shown in Figure 31, when ECs were plated on wells coated with Matrigel without 
the addition of hFN, they showed formation of only a few spontaneous tube 
structures (17.4±1.2 branches per 10000 µm2). On the other hand, when the cells 
were plated on Matrigel with the addiction of hFN, cells formed a characteristic 
capillary-like network (42.8±4.4 branches per 10000 µm2; p<0.05 vs Basal, ANOVA).  
In the presence of RGDechiHCit or c(RGDf[NMe]V), the extent of tube formation 
hFN-induced was significantly reduced (10.03±1.44; 14.11±3.9, respectively; p<0.05 
vs hFN alone, ANOVA; Figure 31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31 Representative phase contrast photomicrographs of bovine aortic endothelial cells (ECs) are 
shown plated on Matrigel. Both c(RGDf[NMe]V) and RGDechiHCit inhibited hFN-induced tube 
formation. Microscopy revealed numbers of network projections (branches) formed in each group after 
12 h of incubation. Data from three experiments in triplicate are summarized in the graph (*=p<0.05 vs 
Basal; #= p<0.05 vs hFN). Error bars show SEM. The black bar corresponds to 100 µm. 
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Looking at in vitro studies results, it is possible affirm that RGDechiHCit ability to 
inhibit hFN-induced cell proliferation is comparable to that of c(RGDf[NMe]V), 
although the half-life is quite reduced.  
A major evidence that is brought up by our results is the peculiar selectivity of 
RGDechiHCit towards EC as compared to c(RGDf[NMe]V). Indeed, RGDechiHCit 
fails to inhibit VSMC proliferation in vitro, opposite to c(RGDf[NMe]V).  
We believe that this feature is due to the selectivity of such a novel compound toward 
v 3. In fact, VSMCs express v 3 only during embryogenesis meanwhile when 
these cells are in culture express other integrins which may be blocked by 
c(RGDf[NMe]V).  
On the contrary, v 3 is expressed by ECs (Lu H., et al., 2006) thus conferring 
RGDechiHCit selectivity toward this cell type. 
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3.4 RGDechiHCit  ANTIANGIOGENIC ACTIVITY: in vivo STUDIES 
 
3.4.1 Wound healing 
 
The examination of full-thickness wounds in the back skin showed that both 
RGDechiHCit and c(RGDf[NMe]V) slowed down healing (Figure 32). At a 
macroscopic observation, the delay in the wound healing in treated rats was evident, 
with raised margins, more extensive wound debris and scab, that persisted for at 
least 7 days after surgery. 
Moreover, histological analysis showed that while control rats presented a dermal 
scar tissue consisting of a well defined and organized fibrous core with minimal 
chronic inflammatory cells, skin wounds exposed to RGDechiHCit or c(RGDf[NMe]V) 
exhibited a retarded repair pattern. Indeed, there was an intense inflammatory 
infiltrate, extended from the wound margin into the region of the panniculus carnosus 
muscle and hypodermis. Moreover, the basal epidermis was disorganized and 
epidermal cell growth failed to achieve re-epithelialization, as shown in figure 32. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 32 Both c(RGDf[NMe]V) and RGDechiHCit slowed down the closure of full thickness punch 
biopsy wounds. Three to five rats were analyzed at each time point. Gross appearance (representative 
digital photographs) after 5 days of the wound treated with pluronic gel containing c(RGDf-[NMe]V), 
RGDechiHCit (10
-6
M) or saline. Diagram of the kinetics of wound closure; *=p<0.05 vs Control; 
#=p<0.05 vs c(RGDf-[NMe]V, ANOVA). Error bars show SEM. Histological analysis revealed a 
retarded repair pattern in treated rats, which is consistent with inhibition of angiogenesis in the 
granulation tissue. Representative sections of excised wounds; 5 µm, ×20 objective (Hematoxylin & 
Eosin, Lectin immunohistochemical staining, Masson’s trichrome). In control animals, epidermal cells. 
growth achieved complete re-epitalization (green arrowheads) and there is a well defined and 
organized fibrous core of scar tissue. Both in c(RGDf[NMe]V) and RGDechiHCit treated rats there is a 
chronic inflammatory infiltrate (red arrows) and lectin staining shows (in brown) the presence of 
vessels in the granulation tissue. 
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3.4.2 Matrigel plugs 
 
After injection, Matrigel implants containing the angiogenic stimulant VEGF (10-5 M) 
formed a plug into which ECs can migrate. Matrigel pellets evidenced a significant 
lower EC infiltration, identified through means of immunohistological lectin staining, in 
c(RGDf[NMe]V) and RGDechiHCit treated plugs respect to VEGF alone 
(VEGF+RGDechiHCit: 0.211±0.034; VEGF+c(RGDf[NMe]V): 0.185±0.027 fold over 
VEGF alone; p<0.05, ANOVA), as depicted in figure 33. 
 
 
 
 
 
Fig. 33  Representative immunohistochemical sections (5 µm) of Matrigel plugs subcutaneously 
injected, at ×20 magnification. ECs were identified by lectin staining, that gave a brown reaction 
product, as described in Methods. Both c(RGDf[NMe]V) and RGDechiHCit treatment reduced the 
number of invading cells from the edge to the core of implanted Matrigel plug. Analysis was conducted 
in 20 randomly chosen cross-sections per each group. *=p<0.05 vs VEGF. Error bars show SEM. 
 
Our data suggest that inhibition of the endothelial integrin system is sufficient to 
inhibit angiogenesis. It is possible to deduce that the higher specificity of 
RGDechiHCit for the endothelium would result in a lower occurrence of side effects 
than the use of less selective inhibitors.  
This is only an indirect evidence, that needs further investigation in more specific 
experimental setups. Indeed, of the wide spectrum of integrins that are expressed on 
the surface of ECs, v 3 receptor has been identified as having an especially 
interesting expression pattern among vascular cells during angiogenesis, vascular 
remodeling, tumor progression and metastasis (Castel S., et al., 2000). The 
relevance of this molecule in angiogenesis and its potential as therapeutic agent has 
been, therefore, well estabilished (Laitinen I., et al., 2009) and in this thesis it was 
shown that RGDechiHCit activity is highly critical for ECs hFN stimulated 
proliferation. 
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3.5 FUNCTIONALISED GOLD NANOPARTICLES: DESIGN, SYNTHESIS AND      
      CHARACTERISATION  
 
3.5.1 Design and synthesis of RGD(GGC)2 and RGD(GC)2 peptides 
 
RGD(GGC)2 peptide (Figure 34) is a chimeric molecule of 12 aminoacids that 
contains two parts encompassing a RGD-sequence and a GGC-motif for both 
integrin targeting and nanoparticle capping effect, respectively. 
The RGD-motif was derived from the c(RGDfK) peptide, a v 3 antagonist, where 
the lysine residue was mutated in glutamic acid one to allow the conjugation to the 
GGC-motif by its -carboxylic group. (GGC)2 is an analog of the previously reported 
capping agent GC15 (Krpetića Z., et al., 2009), containing 7 aminoacid residues (Ac-
AGCGGCG-NH2). 
 
Fig.34  RGD(GGC)2  peptide 
 
LC-MS analysis were performed during the peptide elongation. In particular we 
obtained an unexpected LC-MS spectrum of the peptide after the Fmoc deprotection 
from the glutamic acid residue because the peptide molecular weight, was less 58 
uma respect to the theoretical value (fugure 35). This mass corresponded to the allyl 
alcohol molecular weight and indicated that the allylic group may be eliminated 
during the Fmoc deprotection step with the formation of a cycle between the Gly6and 
Glu5 (glutarimide cyclo) as recently reported in literature (Zhu J., et al., 2008) (Figure 
35). 
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Figure 35 LC-MS of RGD(GGC)2 after Fmoc deprotection from the glutamic acid residue. Two peaks 
are visible in HPLC profile. The most abundant peak (blue line) shows a  molecular weight less 58 
uma respect to the theoretical value present in minor quantity (pink line). 
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Fig. 36 Glutarimide formation between Glu
5
 (blue residue)e Gly
6
(yellow residue (Zhu J., et al., 2008). 
 
This problem was overcame by the substitution of the Gly6 residue with an alanine to 
prevent the glutarimide formation. The new obtained peptide was named RGD(GC)2 
(see Figure 37). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.37 RGD(GC)2 peptide. 
 
During the synthesis of RGD(GC)2, we had a further unexpected problem. Indeed, 
the final peptide LC-MS spectrum showed two peaks corresponding to the same 
molecular weight.  
After a careful study, we deduced that this issue may be due to cysteine residues 
racemisation (Han Y., et al., 1997). 
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It is well known that the racemization process is based on a competition between the 
amino acid activation reaction, rearrangement of the activated species to a 5(4H)-
oxazolone, base-catalyzed abstraction of the amino acid α-proton (enolization) from 
either the activated species directly or a from the oxazolone, and acylation of the 
activated species and/or the oxazolone with an incoming amine nucleophile.  
The presence of base gives dual and opposite effects, because base catalyzes both 
more rapid acylation and leads to more rapid epimerization. Those activation 
protocols that involve the presence of base are likely to result in measurable cysteine 
racemization. As might be expected, the level of racemization decreases by using 
weaker base. Moreover, all of these phenomena are exacerbated with preactivated 
cysteine.  
On the bases of this knowledge we substituted the DIPEA with the weaker base TMP 
in coupling reaction and avoided the amino acid preactivation.  
The final RGD(GC)2 peptide was obtained with a final yield of 25% and a purity of 
99%. The identity of the peptide was confirmed by LC-MS wich gave the uspected 
molecular mass value [M + H]+ of 1099 and an ion [M + 2H]+2of 550.5 (Figure 38A 
and B). 
 
 
Fig. 38 RGD(GC)2 peptide mass spectrum (A); RGD (GC)2 HPLC spectrum and TIC profile. 
 
Finally, we have synthesized a linear and aspecific peptide named (GC)2 reported in 
figure 39, to have a negative control peptide in cellular uptake studies.  
  
 
 
 
 
 
 
 
 
Fig. 39 (GC)2 linear peptide 
 
It  was obtained using the standard Fmoc chemistry, as reported above for RDGgold, 
with a yield of 98% and a purity of 99% (Figure 40 B). The identity of the peptide was 
confirmed by mass value of [M + H]+ of 562.5 for linear peptide (GC)2 as showed in 
figure 40A. 
 
 
 
A B 
550.5 
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Fig. 40 RGD(GC)2 peptide mass spectrum (A); RGD (GC)2 HPLC spectrum and TIC profile. 
 
3.5.2 UV and TEM  characterisation 
 
The UV-Vis spectrum of the gold capped nanosystem obtained (Figure 41A) shows a 
plasmon absorption band at 520 nm typical for gold particles of about 8 nm size and 
the TEM image of the peptide coated gold particles indicates a narrow size 
distribution centered at this size too (Figure 41B). The type of aggregation of particles 
on the sample grid observed here is fairly common for charged particles derived from  
hydrosols and does not suggest that particles are aggregated in solution. Sol stability 
is shown by the absence of any variation of the spectrum profile in 1 hr. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 41 UV characterization of complex RGD(GC)2AuNPs from 15 to 60 minutes (A). TEM analysis of 
functionalised  obtained nanosystem (B). 
 
 
 
 
 
 
 
 
 
 
 
B 
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3.5.3 FTIR characterisation 
 
We have confirmed the binding of RGD(GC)2 to the gold nanoparticles by FTIR 
spectroscopy: the signals obtained was compared to those of the free ligand in 
solution, and the formation of the ligand shell was deduced from the shift of main 
frequencies. A comparison between the FTIR spectrum of the free peptide and that 
of the peptide-protected particles is shown in figure 42.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 42 FTIR spectrum of free RGD(GC)2 peptide (red line) and RGD(GC)2AuNPs (blue line) in 2300-
500 cm
-1
 region. 
 
It can be inferred from the spectra that the particles are bound to the peptide. This is 
concluded observing the vibrational bending modes related to the  amidic groups and 
the carbonyl stretching absorption. Further studies to establish the groups involved in 
binding peptide-gold nanoparticles will be done. 
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3.5.4  NMR Characterisation 
 
We implemented NMR spectroscopy to further verify the binding of the RGD peptide 
to the gold-nanoparticles and to identify key residues involved in this interaction. We 
first focused our attention on the RGD peptide in its apo form and assigned its proton 
resonances. Due to the fast tumbling of this small peptide, no NOE contacts could be 
observed in 2D [1H, 1H] NOESY experiments (Kumar et al., 1980) thus, we recorded 
2D [1H, 1H] ROESY spectra (Bax and Davis, 1985).  
By comparing 2D [1H, 1H] TOCSY  and 2D [1H, 1H] ROESY experiments we were 
able to clearly identify all the different spin-systems for the residues of the RGD 
peptide and also sequentially assign most of them. 
Then, we compared 1D proton and 2D [1H, 1H] TOCSY spectra of the RGD peptide 
with those of the same peptide attached to the gold nanoparticles and with those of 
an analogue peptide whose sequence is encompassing its C-terminal tail, i.e: (CG)2, 
but  is lacking the integrin binding motif.  The strong interaction between peptide and 
AuNPs is already evident in the 1D spectra, where a large broadening of all the 
resonances of the peptides when attached to the nanoparticles can be observed 
(Figure 43).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 43 Comparison of 1D proton spectra of the RGD peptide (A), RGD(GC)2AuNPs nanoparticles (B) 
and (GC)2AuNPs (C). An expansion of the region containing signals from side-chain protons is shown. 
 
From figure 42 is also evident that a structural rearrangement takes place upon 
binding of the peptides to the nanoparticles. Chemical shifts changes are in fact 
widespread throughout the spectra in the aromatic-amide region and also in the 
region of the aliphatic side-chains.  
Cysteines side chains appear highly affected by binding to the nanoparticles in fact 
signals from their Hα protons completely disappear (Figure 43).  
The effect of the interaction with the large inorganic surface of the nanoparticles can 
be better seen in the 2D [1H, 1H] TOCSY spectra (Figure 44).  
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The large broadening of the resonances causes the disappearance of many spin 
systems and highly reduces the quality of the 2D spectra of the RGD peptide when 
bound to the nanoparticles. The use of a cold-probe allow us to partially overcome 
this problem. In fact, spin systems for alanine, arginine, aspartic acid and glutamic 
acid can be easily recognized whereas other spin systems are undergoing excessive 
line broadening (Figure 44).  
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Fig. 44 Comparison of 2D [
1
H, 
1
H] TOCSY spectra of the RGD peptide (left panel) and RGD peptide 
attached to the Au-nanoparticles (right panel). The HN-aliphatic protons correlation region is shown. 
Spin systems assignments are also reported. 
 
It’s worth noting that chemical shifts for the HN of arginine as well as for the Hα 
protons of aspartic acid are clearly changing upon interaction of the peptide with the 
nanoparticles (Figure 44). 
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3.5.3 Cellular Uptake study 
 
To investigate the cellular uptake of the RGD(GC)2AuNPs in comparison with 
(GC)2AuNPs, U-87 MG cells (malignant glioma) as model of human glioblastoma 
were used. To obtain images of the cells after incubation we performed confocal 
microscopy studies (Figure 45). In particular, we  obtained A1 and  B1 images in 
reflection modality in which the RGD(GC)2AuNPs and the (GC)2AuNPs intracellular 
distribution are shown (gold nanoparticles are artificially represented as red spots). 
Instead, images A2 and B2 showed, in transmission modality, the cells distribution. 
The superimposition of previous pictures, resulted in A3 and B3 images, 
demonstrated that both RGD(GC)2AuNPs and (GC)2AuNPs penetrated in target cells 
but RGD(GC)2AuNPs are uptaken qualitatively more efficiently respect to 
(GC)2AuNPs. The increased uptake of RGD(GC)2AuNPs is likely due to receptor 
mediated endocytosis, a cellular uptake mechanism faster than the non specific 
endocytosis. 
 
 
 
 
 
 
 
 
 
 
Fig. 45 RGD(GC)2AuNPs and (GC)2AuNPs (red spots) intracellular distribution by confocal reflection 
microscopy (A1 and B1); cellular distribution by confocal transmission microscopy (A2 and B2), 
superimposition of figure A1 and A2 and of figures B1 and B2 respectively (A3 and B3). 
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4 FUTURE PERSPECTIVES 
 
The present PhD thesis demonstrated that the new and selective v 3 integrin 
ligand, RGDechiHCit, recently designed and  synthesized in our laboratory, has anti-
angiogenic activity. Unfortunately,  in vitro stability studies indicated this compound 
has a low half life in serum probably due to prolyl endopeptidase action. 
To solve this problem we will modify the molecule for example by reducing the 
peptide bond to avoid the protease’s cleavage. Another strategy could be to 
introduce a methyl group at the -amino group of the residue flanking the proline to 
obtain a steric hindrance sufficient to inhibit  the degradation by prolyl endopeptidase.  
In parallel, starting from the results obtained on the RGD based gold nanoparticle (8-
15nm), we will optimize the peptide sequence to improve its cellular uptake and 
obtain a new and selective delivery systems suitable for biotechnological 
applications. For this purpose a first strategy will be to insert an appropriate spacer 
between nanoparticles and the delivering peptide to leave a larger space for peptide-
integrin interaction.  Alternatively, we will insert the targeting motif, RGD, in the 
middle of two (GC)n sequences to favor the interaction with target receptor. The so 
obtained system will be used to deliver drug molecules, like platinum derivatives, 
suitable for cancer treatment (Nam J., et al., 2009). Moreover, we will functionalize 
the gold nanoparticles with opportunely chosen molecules helpful to induce 
intracellular nanoparticles aggregation (100nm) to obtain a system suitable for 
photothermal therapy. Finally, we will quantify the functionalized gold nanoparticles 
incorporated  from the target cells measuring the pixel quantity (gold light in image) 
present in a representative cellular area (the same both for functionalised and not 
gold nanoparticles).  
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Abstract 
Integrins are heterodimeric receptors that play a critical role in cell-cell and cell-matrix 
adhesion processes. Among them, V 3 integrin, that recognizes the aminoacidic 
RGD triad, is reported to be involved in angiogenesis, tissue repair and tumor growth. 
We have recently synthesized a new and selective ligand of V 3 receptor, referred 
to as RGDechiHCit, that contains a cyclic RGD motif and two echistatin moieties.The 
aim of this study is to evaluate in vitro and in vivo the effects of RGDechiHCit. 
Therefore, we assessed its properties in cellular (endothelial cells [EC], and vascular 
smooth muscle cells [VSMC]) and animal models (Wistar Kyoto rats and c57Bl/6 
mice) of angiogenesis.In EC, but not VSMC, RGDechiHCit inhibits intracellular 
mitogenic signaling and cell proliferation. Furthermore, RGDechiHCit blocks the 
ability of EC to form tubes on Matrigel. In vivo, wound healing is delayed in presence 
of RGDechiHCit. Similarly, Matrigel plugs demonstrate an antiangiogenic effect of 
RGDechiHCit. Our data indicate the importance of RGDechiHCit in the selective 
inhibition of endothelial V 3 integrin in vitro and in vivo. Such inhibition opens new 
fields of investigation on the mechanisms of angiogenesis, offering clinical 
implications for treatment of pathophysiological conditions such as cancer, 
proliferative retinopathy and inflammatory disease. 
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Introduction 
Angiogenesis is a complex multistep phenomenon consisting of the sprouting and the 
growth of new capillary blood vessels starting from the pre-existing ones. It requires 
the cooperation of several cell types such as endothelial cells (ECs), vascular smooth 
muscle cells (VSMCs), macrophages, which should be activated, proliferate and 
migrate to invade the extracellular matrix and cause vascular remodeling [1, 2]. The 
angiogenic process is finely tuned by a precise balance of growth and inhibitory 
factors and in mammalians it is normally dormant except for some physiological 
conditions, such as wound healing and ovulation. When this balance is altered, 
excessive or defective angiogenesis occur and the process becomes pathological. 
Excessive angiogenesis gives also rise to different dysfunctions, including cancer, 
eye diseases, rheumatoid arthritis, atherosclerosis, diabetic nephropathy, 
inflammatory bowel disease, psoriasis, endometriosis, vasculitis, and vascular 
malformations [3]. Therefore the discovery of angiogenesis inhibitors would 
contribute to the development of therapeutic treatments for these diseases. 
The integrins are cell adhesion receptors that mediate cell-cell and cell-matrix 
interactions and coordinate signaling allowing a close regulation of physiological 
phenomena including cellular migration, proliferation and differentiation. In particular, 
the V integrins, combined with distinct  subunits, participate in the angiogenic 
process. An extensively studied member of this receptor class is integrin V 3, that is 
strongly overexpressed in activated EC, melanoma, glioblastoma and prostate 
cancers and in granulation tissue, whereas is not detectable in quiescent blood 
vessels or in the dermis and epithelium of normal skin [4-6]. This integrin participates 
in the activation of vascular endothelial growth factor receptor-2 (VEGFR-2), 
providing a survival signal to the proliferating vascular cells during new vessel growth 
[7, 8] and also seems to be essential in the step of vacuolation and lumen formation 
[9]. It has been also reported that V 3 is under the tight control of VEGF: this integrin 
is not expressed in quiescent vessels [10], but VEGF induces V 3 expression in vitro 
and, interestingly, the VEGF and V 3 integrin expression are highly correlated in 
vivo [11, 12]. Therefore, V 3 should be considered a tumor and activated 
endothelium marker.  
V 3 is able of recognizing many proteins of the extracellular matrix, bearing an 
exposed Arg-Gly-Asp (RGD) tripeptide [5, 13, 14]. Even if different integrins 
recognize different proteins containing the RGD triad, many studies have 
demonstrated that the aminoacids flanking the RGD sequence of high-affinity ligands 
appear to be critical in modulating their specificity of interaction with integrin 
complexes [15, 16]. 
Several molecules including peptides containing RGD motif [11] have been recently 
developed as inhibitors of V 3 integrin, in experiments concerning tumor 
angiogenesis, showing a reduction of functional vessel density associated with 
retardation of tumor growth and metastasis formation [6, 17]. So far, the pentapeptide 
c(RGDf[NMe]V), also known as cilengitide (EMD 121974), is the most active 
V 3/ V 5 antagonist reported in literature [18, 19] and is in phase III clinical trials as 
antiangiogenic drug for glioblastoma therapy [15]. The development of more selective 
antiangiogenic molecule would help to minimize the side-effects and increase the 
therapeutic effectiveness. 
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We have recently designed and synthesized a novel and selective peptide 
antagonist, referred to as RGDechiHCit, to visualize V 3 receptor on tumour cells 
[20]. It is a chimeric peptide containing a cyclic RGD motif and two echistatin C-
terminal moieties covalently linked by spacer sequence. Cell adhesion assays have 
shown that RGDechiHCit selectively binds V 3 integrin and does not cross-react 
with V 5 and IIb 3 integrins [20]. Furthermore, PET and SPECT imaging studies 
have confirmed that the peptide localizes on V 3 expressing tumor cells in xenograft 
animal model [21]. Since V 3 is also a marker of activated endothelium, the main 
purpose of this study was to evaluate in vitro and in vivo effects of RGDechiHCit on 
neovascularization. Thus, we first assessed the in vitro peptide properties on bovine 
aortic ECs, and then in vivo, in Wistar Kyoto (WKY) rats and c57BL/6 mice, the ability 
of this cyclic peptide to inhibit angiogenesis. 
 
Methods 
 
Peptides 
 
RGDechiHCit was prepared for the in vitro and in vivo studies as previously 
described [20]. To test the biological effects of RGDechiHCit, we synthesized the 
cyclic pentapeptide c(RGDf[NMe]V), also known as cilengitide or EMD 121974 [14, 
19]. We also investigated RGDechiHCit and c(RGDf[NMe]V) peptides degradation in 
serum. Both peptides were incubated and the resulting solutions were analyzed by 
liquid chromatography/mass spectrometry (LC/MS) at different times. 20uL of human 
serum (Lonza, Basel, Switzerland) were added to 8 uL of a 1 mg/ml solution of either 
RGDechiHCit or c(RGDf[NMe]V) at 37° C. After 1, 2, 4 and 24h, samples were 
centrifuged for 1min at 10000g. Solutions were analyzed by LCQ Deca XP Max 
LC/MS system equipped with a diode-array detector combined with an elctrospray 
ion source and ion trap mass analyzer (ThermoFinnigan, San Jose, CA, USA), using 
a Phenomenex C18 column (250x 2 mm; 5µm; 300 Ǻ) and a linear gradient of H2O 
(0.1%TFA)/CH3CN (0.1%TFA) from 10 to 80% of CH3CN (0.1%TFA) in 30 min at 
flow rate of 200µL/min. 
In vitro studies 
In vitro studies were performed on cell cultures of ECs or VSMCs, cultured in 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, Milan, Italy) as 
previously described and validated [22, 23]. Cell culture plates were filled with 10 
µg/cm2 of human fibronectin (hFN, Millipore , Bedford, MA, USA) as described [24]. 
All experiments were performed in triplicate with cells between passages 5 and 9.  
Cell proliferation assay 
 
Cell cultures were prepared as previously described [25]. Briefly, cells were seeded 
at density of 100000 per well in six-well plates, serum starved, pre-incubated at 37 °C 
for 30’ with c(RGDf[NMe]V) or RGDechiHCit (10-6 M). Proliferation was induced using 
hFN (100 µg/ml). Cell number was measured at 3, 6 and 20 h after stimulation as 
previously described [26, 27].  
 
 
 
70 
 
DNA synthesis 
DNA synthesis was assessed as previously described [27]. Briefly, cells were serum-
starved for 24 h and then incubated in DMEM with [3H]thymidine and 5% FBS. After 
3, 6 and 20 h, cells were fixed with trichloracetic acid (0.05%) and dissolved in 1M 
NaOH. Scintillation liquid was added and [3H]thymidine incorporation was assessed 
as previously described [27].  
VEGF quantification 
VEGF production was measured as previously described [26]. Briefly, ECs were 
seeded at a density of 600000 per well in six well plates, serum starved overnight, 
seeded with c(RGDf[NMe]V) or RGDechiHCit (10-6 M) and then stimulated with hFN 
for 6 hours. Cultured medium was collected and VEGF production was revealed by 
western blot.  
 
Endothelial Matrigel assay 
The formation of network-like structures by ECs on an extracellular matrix (ECM)-like 
3D gel consisting of Matrigel® (BD Biosciences, Bedford, MA, USA), was performed 
as previously described and validated [27, 28]. The six-well multidishes were coated 
with growth factor-reduced Matrigel in according to the manufacturer's instructions. 
ECs (5×104) were seeded with c(RGDf[NMe]V) or RGDechiHCit (10-6 M), in the 
absence (negative control) or presence (100 µg/ml) of hFN [24]. Cells were incubated 
at 37°C for 24h in 1 ml of DMEM. After incubation, ECs underwent differentiation into 
capillary-like tube structures. Tubule formation was defined as a structure exhibiting a 
length four times its width [27]. Network formation was observed using an inverted 
phase-contrast microscope (Zeiss). Representative fields were taken, and the 
average of the total number of complete tubes formed by cells was counted in 15 
random fields by two independent investigators.  
Western blot 
Immunoblot analyses were performed as previously described and validated [23, 28]. 
Mouse monoclonal antibodies to extracellular signal regulated kinase (ERK2) and 
phospho-ERK, anti-rabbit VEGF and actin were from Santa Cruz Biotecnology 
(Santa Cruz, CA, USA). Levels of VEGF were determined using an antibody raised 
against VEGF-165 (Santa Cruz Biotechnology) [26]. Experiments were performed in 
triplicate to ensure reproducibility. Data are presented as arbitrary densitometry units 
(ADU) after normalization for the total corresponding protein or actin as internal 
control [24]. 
In vivo studies 
Wound healing assay was performed on 14-week-old (weight 293±21 g) 
normotensive WKY male rats (Charles River Laboratories, Calco (LC), Italy; n=18), 
and Matrigel plugs experiments were carried out on 16-week-old (weight 33±4 g) 
c57BL/6 mice (Charles River Laboratories, Milan, Italy; n=13). All animal procedures 
were performed in accordance with the Guide for the Care and Use of Laboratory 
Animals published by the National Institutes of Health in the United States (NIH 
Publication No. 85- 23, revised 1996) and approved by the Ethics Committee for the 
Use of Animals in Research of “Federico II” University [23]. 
Wound Healing 
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The rats (n=18) were anesthetized using vaporized isoflurane (4%, Abbott) and 
maintained by mask ventilation (isoflurane 1.8%) [29]. The dorsum was shaved by 
applying a depilatory creme (Veet, Reckitt-Benckiser, Milano, Italy) and disinfected 
with povidone iodine scrub. A 20 mm diameter open wound was excised through the 
entire thickness of the skin, including the panniculus carnosus layer, as described 
and validated [1, 28]. Pluronic gel (30%) containing (10-6 M) c(RGDf[NMe]V) (n=6), 
RGDechiHCit (n=7), or saline (n=5) was placed daily directly onto open wounds, then 
covered with a sterile dressing. Two operators blinded to the identity of the sample 
examined and measured wound areas every day, for 8 days. Direct measurements of 
wound region were determined by digital planimetry (pixel area), and subsequent 
analysis was performed using a computer-assisted image analyzer (ImageJ software, 
version 1.41, National Institutes of Health, Bethesda, MD, USA). Wound healing was 
quantified as a percentage of the original injury size. Eight days after wounding, rats 
were euthanized. Wounds did not show sign of infection. A portion of the lesion and 
adiacent normal skin were excised, fixed by immersion in phosphate buffered saline 
(PBS, 0.01 M, pH 7.2-7.4)/formalin and then embedded in paraffin to be processed 
for immunohistology, as described [1]. 
 
Matrigel Plugs 
 
Mice (n=13), anesthetized as described above, were injected subcutaneously 
midway on the dorsal side, using sterile conditions, with 0.2 ml of Matrigel® basement 
matrix, mixed with 10-6M VEGF and 10-5M c(RGDf[NMe]V) (n=4), 10-6M VEGF and 
10-5M RGDechiHCit (n=5), or 10-6M VEGF alone (n=4). After seven days, mice were 
euthanized and the implanted plugs were harvested with adjacent tissue to be fixed 
in 10% neutral-buffered formalin solution and then embedded in paraffin. Invading 
ECs were quantified by analysis of lectin immunostained sections, as described [1, 
2]. 
 
Histology 
 
All tissues were cut in 5 µm sections and slides were counterstained with a standard 
mixture of hematoxylin and eosin. For Masson’s trichrome staining of collagen fibers, 
useful to assess the scar tissue formation, slides were stained with Weigert 
Hematoxylin (Sigma-Aldrich, St. Louis, MO, USA) for 10 minutes, rinsed in PBS 
(Invitrogen) and then stained with Biebrich scarlet-acid fuchsin (Sigma-Aldrich) for 5 
minutes. Slides were rinsed in PBS and stained with 
phosphomolybdic/phosphotungstic acid solution (Sigma-Aldrich) for 5 minutes then 
stained with light green (Sigma-Aldrich) for 5 minutes [30]. ECs were identified by 
lectin immunohistochemical staining (Sigma-Aldrich) [2] and quantitative analysis 
was performed using digitized representative high resolution photographic images, 
with a dedicated software (Image Pro Plus; Media Cybernetics, Bethesda, MD, USA) 
as previously described [28]. 
 
Data presentation and statistical analysis 
 
All data are presented as the mean value±SEM. Statistical differences were 
determined by one-way or two-way ANOVA and Bonferroni post hoc testing was 
performed where applicable. A p value less than 0.05 was considered to be 
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significant. All the statistical analysis and the evaluation of data were performed 
using GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA, USA). 
 
Results 
 
Peptides 
 
RGDechiHCit and c(RGDf[NMe]V) peptides stabilities were evaluated in serum. The 
degradation of the peptides were followed by LC/MS. The reversed-phase high 
performance liquid chromatography (RP-HPLC) of RGDechiHCit before the serum 
incubation showed a single peak at tr=11.82 min corresponding to the complete 
sequence (theoretical MW=2100.1 g mol-1) as indicated by the [M+H]+, [M+2H]2+ and 
[M+3H]+3 molecular ion adducts in the MS spectrum (Figure 1A). After 1h, 
chromatography showed two peaks, ascribable to RGDechiHCit and to a fragment of 
the complete sequence (theoretical MW=1929.1 g mol-1), respectively, as confirmed 
by MS spectrum. Finally, after 24h a further peak at tr=10.93 min corresponding to 
another RGDechiHCit degradation product (theoretical MW=1775.8 g mol-1) 
appeared, as indicated by the molecular ion adducts in the MS spectrum, although 
the peaks attributed to the RGDechiHCit and to the first fragment were still present 
(Figure 1B). 
In contrast with RGDechiHCit, c(RGDf[NMe]V) showed high stability in serum. The 
RP-HPLC profile of the peptide before the incubation showed a single peak at 
tr=16.64 min, ascribable to the complete sequence by the MS spectrum (Figure 1C). 
After 24h of incubation chromatogram and mass profiles failed to identify any 
degradation product (Figure 1D).  
Since RGDechiHCit showed a low stability, we replenished antagonists every six 
hours in experiments involving chronic exposure. 
 
In vitro experiments 
Cell proliferation and DNA synthesis 
 
Because angiogenesis is intimately associated to EC proliferation, we explored the 
effects of RGDechiHCit and c(RGDf[NMe]V) on hFN-stimulated EC. In this cellular 
setting, after 6 hours, both αvβ3 integrin antagonists inhibited in a comparable way 
the ability of hFN to induce proliferation (hFN: +1.98±0.6; hFN+RGDechiHCit: 
+0.58±0.24; hFN+c(RGDf[NMe]V): +0.6±0.38 fold over basal; p<0.05, ANOVA) as 
depicted in Figure 2A. After 20 hours such inhibitory effect was less marked (Figure 
2A). In VSMC there was only a trend of an anti-proliferative effect for these peptides, 
due to the less evident action of hFN in this specific cellular setting (hFN: +1.21±0.1; 
hFN+RGDechiHCit: +0.93±0.07; hFN+c(RGDf[NMe]V): +0.9±0.09 fold over basal; 
NS; Figure 3A). 
The effects of RGDechiHCit and c(RGDf[NMe]V) on EC and VSMC proliferation were 
also measured by assessing the incorporation of [3H]Thymidine in response to hFN. 
This assay confirmed the anti-proliferative action of both these peptides, which is 
more evident after 6 hours and in ECs (hFN: +1.84±0.24; hFN+RGDechiHCit: 
+1.02±0.2; hFN+c(RGDf[NMe]V): +1.09±0.07 fold over basal; p<0.05, ANOVA; 
Figure 2B). On the contrary, the effect of RGDechiHCit on VSMC did not reach 
statistical significance in comparison to the c(RGDf[NMe]V) used as control (Figure 
3B). 
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Effects on cellular signal transduction 
 
Since hFN-mediated activation of ERK2 is linked to angiogenesis [16, 24, 31], we 
analyzed the ability of RGDechiHCit and c(RGDf[NMe]V) to inhibit hFN-induced 
phosphorylation of ERK2 in EC and VSMC. In accordance with the results on cell 
proliferation and [3H]Thymidine incorporation, in EC both RGDechiHCit and 
c(RGDf[NMe]V) significantly inhibited the hFN-induced phosphorylation of mitogen-
activated protein ERK2 (Figure 2C). Also, in VSMC, there was no significant 
inhibition of ERK2 phosphorylation by the RGDechiHCit compund c(RGDf[NMe]V) 
(Figure 3C). 
 
Evaluation of VEGF expression 
 
Angiogenesis is largely dependent on ERK2 activation, which in turn promotes 
cellular proliferation and expression of VEGF. This cytokine promotes infiltration of 
inflammatory cells, proliferation of ECs and VSMCs and sustains the proangiogenic 
phenotype [12]. The early release (6 hours) of the cytokine is therefore an important 
readout when studying angiogenesis in vitro. On these grounds, we assessed the 
expression levels of this pivotal proangiogenetic factor in EC after 6 hours of 
stimulation with hFN. hFN induces VEGF release and such response was blunted by 
incubation with either integrin antagonist, as depicted in Figure 4 (hFN: +18.9±1.02; 
hFN+RGDechiHCit: +2.44±0.76; hFN+c(RGDf[NMe]V): +3.19±0.73 fold over basal, 
ADU; p<0.05, ANOVA). 
 
Endothelial Matrigel assay 
 
The formation of capillary-like tube structures in the ECM by ECs is a pivotal step in 
angiogenesis and is also involved in cell migration and invasion [26]. To evaluate any 
potential antiangiogenic activity of our novel integrin antagonist, in vitro angiogenesis 
assays were conducted by evaluating hFN-induced angiogenesis of ECs on Matrigel. 
As shown in Figure 5, when ECs were plated on wells coated with Matrigel without 
the addition of hFN, they showed formation of only a few spontaneous tube 
structures (17.4±1.2 branches per 10000 µm2). On the other hand, when the cells 
were plated on Matrigel with the addiction of hFN, cells formed a characteristic 
capillary-like network (42.8±4.4 branches per 10000 µm2; p<0.05 vs Basal, ANOVA). 
In the presence of RGDechiHCit or c(RGDf[NMe]V), the extent of tube formation 
hFN-induced was significantly reduced (10.03±1.44; 14.11±3.9, respectively; p<0.05 
vs hFN alone, ANOVA; Figure 5). 
 
In vivo experiments 
Wound healing 
 
The examination of full-thickness wounds in the back skin showed that both 
RGDechiHCit and c(RGDf[NMe]V) slowed down healing (Figure 6). At a macroscopic 
observation, the delay in the wound healing in treated rats was evident, with raised 
margins, more extensive wound debris and scab, that persisted for at least 7 days 
after surgery. Moreover, histological analysis showed that while control rats 
presented a dermal scar tissue consisting of a well defined and organized fibrous 
core with minimal chronic inflammatory cells, skin wounds exposed to RGDechiHCit 
or c(RGDf[NMe]V) exhibited a retarded repair pattern. Indeed, there was an intense 
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inflammatory infiltrate, extended from the wound margin into the region of the 
panniculus carnosus muscle and hypodermis. Moreover, the basal epidermis was 
disorganized and epidermal cell growth failed to achieve re-epithelialization, as 
shown in Figure 6. 
 
Matrigel plugs 
 
After injection, Matrigel implants containing the angiogenic stimulant VEGF (10-5 M) 
formed a plug into which ECs can migrate. Matrigel pellets evidenced a significant 
lower EC infiltration, identified through means of immunohistological lectin staining, in 
c(RGDf[NMe]V) and RGDechiHCit treated plugs respect to VEGF alone 
(VEGF+RGDechiHCit: 0.211±0.034; VEGF+c(RGDf[NMe]V): 0.185±0.027 fold over 
VEGF alone; p<0.05, ANOVA), as depicted in Figure 7. 
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Discussion 
 
In the present study, we evaluated the anti-angiogenic properties of RGDechiHCit 
peptide in vitro on EC and VSMC cells and in vivo on animal models of rats and 
mice. The data here reported recapitulate the well-known antiangiogenic properties 
of c(RGDf[NMe]V), that was used as control. We previously described the design and 
synthesis of RGDechiHCit, a novel and selective ligand for V 3 integrin, containing a 
cyclic RGD motif and two echistatin C-terminal moieties [20]. In vitro studies showed 
that this molecule is able to selectively bind V 3 integrin and not to cross-react with 
other type of integrins. Furthermore, PET and SPECT imaging studies have 
confirmed that the peptide localizes on V 3 expressing tumor cells in xenograft 
animal model [21]. Given the presence in the molecule of the RGD sequence it was 
obvious to speculate that RGDechiHCit acted as an antagonist. Our report is the first 
evidence that our peptide acts as antagonist for V 3 integrin. Its ability to inhibit hFN-
induced cell proliferation is comparable to that of c(RGDf[NMe]V), although the half-
life is quite reduced. 
A major evidence that is brought up by our results is the peculiar selectivity of 
RGDechiHCit towards EC, as compared to c(RGDf[NMe]V). Indeed, RGDechiHCit 
fails to inhibit VSMC proliferation in vitro, opposite to c(RGDf[NMe]V). We believe 
that this feature is due to the selectivity of such a novel compound towards V 3. 
Indeed, VSMCs express V 3 only during embryogenesis [31], but express other 
integrins which may be blocked by c(RGDf[NMe]V). On the contrary, V 3 is 
expressed by ECs [8], thus conferring RGDechiHCit selectivity toward this cell type. 
This issue is relevant cause the effect in vivo is similar between the two antagonists 
on wound healing and Matrigel plugs invasion. Indeed, our data suggest that 
inhibition of the endothelial integrin system is sufficient to inhibit angiogenesis. It is 
possible to speculate that the higher specificity of RGDechiHCit for the endothelium 
would result in a lower occurrence of side effects than the use of less selective 
inhibitors. This is only an indirect evidence, that needs further investigation in more 
specific experimental setups. Indeed, of the wide spectrum of integrins that are 
expressed on the surface of ECs, V 3 receptor has been identified as having an 
especially interesting expression pattern among vascular cells during angiogenesis, 
vascular remodeling, tumor progression and metastasis [6, 32, 33]. What is more, 
two pathways of angiogenesis have been recently identified based on the related but 
distinct integrins V 3 and V 5 [4]. In particular, V 3 integrin activates VEGF 
receptors and inhibition of 3 subunit has been shown to reduce phosphorylation of 
VEGF receptors [7], thereby limiting the biological effects of VEGF [1]. Further, 
Mahabeleshwar and coworkers have shown the intimate interaction occurring 
between V 3 integrin and the VEGFR-2 in
 primary human EC [12]. The relevance of 
this molecule to angiogenesis and its potential as a therapeutic target has, therefore, 
been well established [34, 35] and in this report we show that its activity is highly 
critical for both hFN or VEGF-stimulated ECs proliferation. 
Our results concerning RGDechiHCit in angiogenic processes are of immediate 
translational importance, because deregulation of angiogenesis is involved in several 
clinical conditions including cancer, ischemic, and inflammatory diseases 
(atherosclerosis, rheumatoid arthritis, or age-related macular degeneration) [34-36]. 
Therefore, the research for drugs able to modulate angiogenesis constitutes a crucial 
investigation field. Since RGDechiHCit is rapidly removed in serum it is possible to 
increase its effect by engineering the molecule to elongate its lifespan. In the present 
paper we circumvented this issue by increasing the times of application of the drug 
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both in vitro and in vivo, or by reducing the times of observation. This issue can be 
solved by the design use of a more stable peptidic structure of RGDechiHCit. Clearly, 
further investigations are also needed to fully understand the basic cell biological 
mechanisms underlying growth factor receptors and integrin function during 
angiogenesis. The knowledge of molecular basis of this complex mechanism remains 
a challenge of fascinating interest, with clinical implications for treatment of a large 
number of pathophysiological conditions including but not limited to solid tumors [17, 
37], diabetic retinopathy [38, 39] and inflammatory disease [36].  
 
Competing interests 
 
The authors declare that they have no competing interests. 
 
Authors’contributions 
 
GS and GI designed research; GS, MFB, MDS, DS, AA, CGD and MS carried out the 
experiments; GS and GI performed the statistical analysis; GS, GI, ADG and LZ 
drafted the manuscript; GS, BT, CP and GI supervised the project; GS and MFB 
equally contributed to this work. All authors read and approved the final manuscript. 
77 
 
References 
 
1. Santulli G, Ciccarelli M, Palumbo G, Campanile A, Galasso G, Ziaco B, 
Altobelli GG, Cimini V, Piscione F, D'Andrea LD, et al: In vivo properties of 
the proangiogenic peptide QK. J Transl Med 2009, 7:41. 
2. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, 
Burchfield J, Fox H, Doebele C, Ohtani K, et al: MicroRNA-92a controls 
angiogenesis and functional recovery of ischemic tissues in mice. 
Science 2009, 324:1710-1713. 
3. Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications 
and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22. 
4. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA: Differential 
alphav integrin-mediated Ras-ERK signaling during two pathways of 
angiogenesis. J Cell Biol 2003, 162:933-943. 
5. Takahashi S, Moser M, Montanez E, Nakano T, Seo M, Backert S, Inoue I, 
Awata T, Katayama S, Komoda T, Fassler R: The fibronectin RGD motif is 
required for multiple angiogenic events during early embryonic 
development. Arterioscler Thromb Vasc Biol 2010, 30:e1. 
6. Castel S, Pagan R, Garcia R, Casaroli-Marano RP, Reina M, Mitjans F, Piulats 
J, Vilaro S: Alpha v integrin antagonists induce the disassembly of focal 
contacts in melanoma cells. Eur J Cell Biol 2000, 79:502-512. 
7. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F: Role of 
alphavbeta3 integrin in the activation of vascular endothelial growth 
factor receptor-2. Embo J 1999, 18:882-892. 
8. Lu H, Murtagh J, Schwartz EL: The microtubule binding drug laulimalide 
inhibits vascular endothelial growth factor-induced human endothelial 
cell migration and is synergistic when combined with docetaxel 
(taxotere). Mol Pharmacol 2006, 69:1207-1215. 
9. Bayless KJ, Salazar R, Davis GE: RGD-dependent vacuolation and lumen 
formation observed during endothelial cell morphogenesis in three-
dimensional fibrin matrices involves the alpha(v)beta(3) and 
alpha(5)beta(1) integrins. Am J Pathol 2000, 156:1673-1683. 
10. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-
Stevenson WG, Quigley JP, Cheresh DA: Localization of matrix 
metalloproteinase MMP-2 to the surface of invasive cells by interaction 
with integrin alpha v beta 3. Cell 1996, 85:683-693. 
11. Abumiya T, Lucero J, Heo JH, Tagaya M, Koziol JA, Copeland BR, del Zoppo 
GJ: Activated microvessels express vascular endothelial growth factor 
and integrin alpha(v)beta3 during focal cerebral ischemia. J Cereb Blood 
Flow Metab 1999, 19:1038-1050. 
12. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV: Mechanisms of 
integrin-vascular endothelial growth factor receptor cross-activation in 
angiogenesis. Circ Res 2007, 101:570-580. 
13. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman SL, Arnaout 
MA: Crystal structure of the extracellular segment of integrin alpha 
Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296:151-
155. 
14. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H: Arg-Gly-
Asp constrained within cyclic pentapeptides. Strong and selective 
78 
 
inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS 
Lett 1991, 291:50-54. 
15. Schottelius M, Laufer B, Kessler H, Wester HJ: Ligands for mapping 
alphavbeta3-integrin expression in vivo. Acc Chem Res 2009, 42:969-980. 
16. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA: Integrin alphavbeta3 
requirement for sustained mitogen-activated protein kinase activity 
during angiogenesis. J Cell Biol 1998, 140:1255-1263. 
17. Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, Wu Y, Gong Z, Li A, Xu S, et al: 
JWA regulates melanoma metastasis by integrin alpha(V)beta(3) 
signaling. Oncogene 2009. 
18. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, 
Wynendaele W, Drevs J, Verweij J, van Oosterom AT: Phase I and 
pharmacokinetic study of continuous twice weekly intravenous 
administration of Cilengitide (EMD 121974), a novel inhibitor of the 
integrins alphavbeta3 and alphavbeta5 in patients with advanced solid 
tumours. Eur J Cancer 2003, 39:917-926. 
19. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, 
Goodman SL, Kessler H: N-Methylated cyclic RGD peptides as highly 
active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 
1999, 42:3033-3040. 
20. Del Gatto A, Zaccaro L, Grieco P, Novellino E, Zannetti A, Del Vecchio S, 
Iommelli F, Salvatore M, Pedone C, Saviano M: Novel and selective 
alpha(v)beta3 receptor peptide antagonist: design, synthesis, and 
biological behavior. J Med Chem 2006, 49:3416-3420. 
21. Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, 
Papaccioli A, Sommella J, Panico M, Speranza A, et al: Imaging of 
alphavbeta3 expression by a bifunctional chimeric RGD peptide not 
cross-reacting with alphavbeta5. Clin Cancer Res 2009, 15:5224-5233. 
22. Ciccarelli M, Cipolletta E, Santulli G, Campanile A, Pumiglia K, Cervero P, 
Pastore L, Astone D, Trimarco B, Iaccarino G: Endothelial beta2 adrenergic 
signaling to AKT: role of Gi and SRC. Cell Signal 2007, 19:1949-1955. 
23. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, 
Paudice A, Elia A, Santulli G, Campanile A, et al: AKT participates in 
endothelial dysfunction in hypertension. Circulation 2004, 109:2587-2593. 
24. Illario M, Cavallo AL, Monaco S, Di Vito E, Mueller F, Marzano LA, Troncone 
G, Fenzi G, Rossi G, Vitale M: Fibronectin-induced proliferation in thyroid 
cells is mediated by alphavbeta3 integrin through Ras/Raf-1/MEK/ERK 
and calcium/CaMKII signals. J Clin Endocrinol Metab 2005, 90:2865-2873. 
25. Iaccarino G, Smithwick LA, Lefkowitz RJ, Koch WJ: Targeting Gbeta gamma 
signaling in arterial vascular smooth muscle proliferation: a novel 
strategy to limit restenosis. Proc Natl Acad Sci U S A 1999, 96:3945-3950. 
26. Iaccarino G, Ciccarelli M, Sorriento D, Galasso G, Campanile A, Santulli G, 
Cipolletta E, Cerullo V, Cimini V, Altobelli GG, et al: Ischemic 
neoangiogenesis enhanced by beta2-adrenergic receptor 
overexpression: a novel role for the endothelial adrenergic system. Circ 
Res 2005, 97:1182-1189. 
27. Ciccarelli M, Santulli G, Campanile A, Galasso G, Cervero P, Altobelli GG, 
Cimini V, Pastore L, Piscione F, Trimarco B, Iaccarino G: Endothelial alpha1-
adrenoceptors regulate neo-angiogenesis. Br J Pharmacol 2008, 153:936-
946. 
79 
 
28. Sorriento D, Ciccarelli M, Santulli G, Campanile A, Altobelli GG, Cimini V, 
Galasso G, Astone D, Piscione F, Pastore L, et al: The G-protein-coupled 
receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing 
nuclear accumulation of IkappaB alpha. Proc Natl Acad Sci U S A 2008, 
105:17818-17823. 
29. Sorriento D, Santulli G, Fusco A, Anastasio A, Trimarco B, Iaccarino G: 
Intracardiac Injection of AdGRK5-NT Reduces Left Ventricular 
Hypertrophy by Inhibiting NF-{kappa}B-Dependent Hypertrophic Gene 
Expression. Hypertension 2010, 56:696-704. 
30. Santulli G, Illario M, Palumbo G, Sorriento D, Cipolletta E, Trimarco V, Del 
Giudice C, Ciccarelli M, Trimarco B, Iaccarino G: CaMK4 partecipates in the 
settings of the hypertensive phenotype: a human genome wide analysis 
supported by animal model. Eur Heart J 2009, 30(Suppl.1):161. 
31. Astrof S, Hynes RO: Fibronectins in vascular morphogenesis. 
Angiogenesis 2009, 12:165-175. 
32. Zaccaro L, Del Gatto A, Pedone C, Saviano M: Peptides for tumour therapy 
and diagnosis: current status and future directions. Curr Med Chem 2009, 
16:780-795. 
33. Verbisck NV, Costa ET, Costa FF, Cavalher FP, Costa MD, Muras A, Paixao 
VA, Moura R, Granato MF, Ierardi DF, et al: ADAM23 negatively modulates 
alpha(v)beta(3) integrin activation during metastasis. Cancer Res 2009, 
69:5546-5552. 
34. Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, Leppanen 
P, Yla-Herttuala S, Holzlwimmer G, Walch A, et al: Evaluation of 
alphavbeta3 integrin-targeted positron emission tomography tracer 18F-
galacto-RGD for imaging of vascular inflammation in atherosclerotic 
mice. Circ Cardiovasc Imaging 2009, 2:331-338. 
35. Furundzija V, Fritzsche J, Kaufmann J, Meyborg H, Fleck E, Kappert K, 
Stawowy P: IGF-1 increases macrophage motility via PKC/p38-dependent 
alphavbeta3-integrin inside-out signaling. Biochem Biophys Res Commun 
2010, 394:786-791. 
36. Vanderslice P, Woodside DG: Integrin antagonists as therapeutics for 
inflammatory diseases. Expert Opin Investig Drugs 2006, 15:1235-1255. 
37. Tani N, Higashiyama S, Kawaguchi N, Madarame J, Ota I, Ito Y, Ohoka Y, 
Shiosaka S, Takada Y, Matsuura N: Expression level of integrin alpha 5 on 
tumour cells affects the rate of metastasis to the kidney. Br J Cancer 
2003, 88:327-333. 
38. Crawford TN, Alfaro DV, 3rd, Kerrison JB, Jablon EP: Diabetic retinopathy 
and angiogenesis. Curr Diabetes Rev 2009, 5:8-13. 
39. Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, 
Huebert N, Bursell SE, Clermont AC, et al: Studies with an orally 
bioavailable alpha V integrin antagonist in animal models of ocular 
vasculopathy: retinal neovascularization in mice and retinal vascular 
permeability in diabetic rats. J Pharmacol Exp Ther 2008, 324:894-901. 
 
80 
 
 
 
 
 
81 
 
 
 
 
82 
 
Figures legends 
 
Figure 1  
Reversed-phase high performance liquid chromatography (RP-HPLC) 
chromatograms and mass spectra at t=0 and t=24 h for RGDechiHCit (A and B) and 
c(RGDf[NMe]V) (C and D), respectively. In panel B the chromatographic peaks at 
tr=11.70 ( ), 12.04 ( ) and 10.93 min ( ) are marked. 
Figure 2 
 In vitro effects of c(RGDf[NMe]V) and RGDechiHCit on cell proliferation (Panel A) 
and DNA synthesis assessed by [3H]thymidine incorporation (Panel B) in bovine 
aortic endothelial cells (EC). Given alone, c(RGDf[NMe]V) or RGDechiHCit did not 
affect EC proliferation. Neverteless, incubation with these V 3 integrin antagonists 
inhibited in a comparable way EC proliferation in response to the mitogenic stimulus, 
hFN. All experiments depicted in this figure were performed from three to six times in 
duplicate (*= p<0.05 vs Basal, #= p<0.05 vs hFN). Panel C. In vitro effects of 
c(RGDf[NMe]V) and RGDechiHCit on EC signal transduction. Extracellular signal 
regulated kinase (ERK)/mitogen-activated protein kinase activation: western blot of 
activated (phosphorylated: pERK) ERK2 after hFN-stimulation. Equal amounts of 
proteins were confirmed via blotting for total ERK. Densitometric analysis (bar graph) 
showed that hFN stimulation caused ERK activation (*= p<0.05 vs Basal) and that 
treatment with V 3 antagonists blunted such activation (#= p<0.05 vs hFN). Error 
bars show SEM. Representative blots are shown in the inset. 
 
Figure 3  
In vitro effects of c(RGDf[NME]V) and RGDechiHCit on vascular smooth muscle cell 
(VSMC) cell proliferation (Panel A) and DNA synthesis assayed by [3H]thymidine 
incorporation (Panel B). In this cellular setting, hFN induced a mitogenic stimulus, 
appreciable especially at 20h. c(RGDf[NMe]V) but not RGDechiHCit at that time-
point induced an attenuation of such proliferative response. All experiments were 
performed from three to five times in triplicate (*= p<0.05 vs Basal; #= p<0.05 vs 
hFN). In vitro effects of c(RGDf[NMe]V) and RGDechiHCit on VSMC signal 
transduction were represented in Panel C. Extracellular signal regulated kinase 
(ERK)/mitogen-activated protein kinase activation: western blot of activated 
(phosphorylated: pERK) ERK2 after hFN-stimulation. Blots were then stripped and 
reprobed for either total ERK as a loading control. Densitometric analysis (bar graph) 
showed that hFN induced ERK phosphorylation (*= p<0.05 vs Basal) and that 
treatment with c(RGDf[NMe]V) but not RGDechiHCit decreased such activation (#= 
p<0.05 vs hFN). Error bars show SEM. Representative blots are presented in the 
inset. 
 
Figure 4 
VEGF production in bovine aortic endothelial cells (ECs) measured by Western blot 
(inset). Shown are VEGF levels after 6 hours of serum starvation. Equal amount of 
proteins were verified by blotting for actin. Quantification of western blot from all 
experiments demonstrated that hFN was able to increase VEGF production (*= 
p<0.05 vs Basal), while after c(RGDf[NMe]V) or RGDechiHCit treatment VEGF levels 
returned to basal conditions (#= p<0.05 vs hFN). All data derived from three different 
experiments performed in duplicate. The results were expressed as fold increased 
with respect to the basal condition in untreated samples. Error bars show SEM. 
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Figure 5  
Representative phase contrast photomicrographs of bovine aortic endothelial cells 
(ECs) are shown plated on Matrigel. Both c(RGDf[NMe]V) and RGDechiHCit 
inhibited hFN-induced tube formation. Microscopy revealed numbers of network 
projections (branches) formed in each group after 12 h of incubation. Data from three 
experiments in triplicate are summarized in the graph (*=p<0.05 vs Basal; #= p<0.05 
vs hFN). Error bars show SEM. The black bar corresponds to 100 µm. 
 
Figure 6 
 Both c(RGDf[NMe]V) and RGDechiHCit slowed down the closure of full thickness 
punch biopsy wounds. Three to five rats were analyzed at each time point. Gross 
appearance (representative digital photographs) after 5 days of the wound treated 
with pluronic gel containing c(RGDf-[NMe]V), RGDechiHCit (10-6M) or saline. 
Diagram of the kinetics of wound closure; *=p<0.05 vs Control; #=p<0.05 vs c(RGDf-
[NMe]V, ANOVA). Error bars show SEM. Histological analysis revealed a retarded 
repair pattern in treated rats, which is consistent with inhibition of angiogenesis in the 
granulation tissue. Representative sections of excised wounds; 5 µm, ×20 objective 
(Hematoxylin & Eosin, Lectin immunohistochemical staining, Masson’s trichrome). In 
control animals, epidermal cell growth achieved complete re-epitalization (green 
arrowheads) and there is a well defined and organized fibrous core of scar tissue. 
Both in c(RGDf[NMe]V) and RGDechiHCit treated rats there is a chronic 
inflammatory infiltrate (red arrows) and lectin staining shows (in brown) the presence 
of vessels in the granulation tissue. 
 
Figure 7  
Representative immunohistochemical sections (5 µm) of Matrigel plugs 
subcutaneously injected, at ×20 magnification. ECs were identified by lectin staining, 
that gave a brown reaction product, as described in Methods. Both c(RGDf[NMe]V) 
and RGDechiHCit treatment reduced the number of invading cells from the edge to 
the core of implanted Matrigel plug. Analysis was conducted in 20 randomly chosen 
cross-sections per each group. *=p<0.05 vs VEGF. Error bars show SEM. 
 
 
 
 
 
